_MEMBER_att_D_AD_1 - 0.9-1.1,_MEMBER_att_D_AD_1 - 4.5-5.5,_MEMBER_att_D_AD_1 - 9.0-11.0,_LogP_att_D_AD_1 - 0.9-1.1,_LogP_att_D_AD_1 - 4.5-5.5,_LogP_att_D_AD_1 - 9.0-11.0,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,1,-6.4,-3.5,-2.8,GO:0045637,regulation of myeloid cell differentiation,M111,3,0
1,1,1,-3.4,-2.8,-2.3,GO:0045598,regulation of fat cell differentiation,M111,3,0
1,1,1,-9.1,-4.6,-2.6,GO:0002521,leukocyte differentiation,M111,3,0
1,1,1,-7.1,-3.5,-2.4,GO:0001501,skeletal system development,M111,3,0
1,1,1,-9.7,-3.9,-2.6,GO:0061448,connective tissue development,M111,3,0
1,1,1,-8.8,-8.3,-3.3,GO:0048568,embryonic organ development,M111,3,0
1,1,1,-9.8,-3.3,-5.1,GO:0006351,DNA-templated transcription,M111,3,0
1,1,1,-9.8,-5.9,-2.4,GO:1902893,regulation of miRNA transcription,M111,3,0
1,1,1,-7,-5.6,-2.5,GO:0030099,myeloid cell differentiation,M111,3,0
1,1,1,-8.5,-6.3,-3.6,GO:1903706,regulation of hemopoiesis,M111,3,0
1,1,1,-13,-6.5,-3.4,GO:0030097,hemopoiesis,M111,3,0
1,1,1,-9.6,-3.3,-5,GO:0032774,RNA biosynthetic process,M111,3,0
1,1,1,-5.1,-3.4,-4.1,GO:0008283,cell population proliferation,M111,3,0
1,1,1,-9.7,-5.6,-2.3,GO:2000628,regulation of miRNA metabolic process,M111,3,0
1,1,1,-5.8,-2.5,-3.7,M285,PID HNF3A PATHWAY,M111,3,0
1,1,1,-2.8,-2.1,-2.4,GO:0048469,cell maturation,M111,3,0
1,1,1,-10,-3.4,-2.7,hsa05202,Transcriptional misregulation in cancer,M111,3,0
1,1,1,-4.2,-2.8,-2.9,GO:0048705,skeletal system morphogenesis,M111,3,0
1,1,1,-8.2,-4.8,-2.1,GO:0043009,chordate embryonic development,M111,3,0
1,1,1,-11,-5.8,-2.3,GO:0140747,regulation of ncRNA transcription,M111,3,0
1,1,1,-7.9,-4.8,-2.1,GO:0009792,embryo development ending in birth or egg hatching,M111,3,0
1,1,0,-2.6,-3.8,0,GO:0031076,embryonic camera-type eye development,M110,2,0
1,1,0,-4.7,-3.1,0,WP4216,Chromosomal and microsatellite instability in colorectal cancer,M110,2,0
1,1,0,-4.2,-4.3,0,GO:0045639,positive regulation of myeloid cell differentiation,M110,2,0
1,1,0,-3.5,-2.4,0,GO:0034612,response to tumor necrosis factor,M110,2,0
1,1,0,-6.1,-3.6,0,WP2853,Endoderm differentiation,M110,2,0
1,1,0,-7.3,-6.3,0,GO:0048598,embryonic morphogenesis,M110,2,0
1,1,0,-4.4,-2.2,0,GO:2000377,regulation of reactive oxygen species metabolic process,M110,2,0
1,1,0,-4.1,-4.7,0,GO:0071353,cellular response to interleukin-4,M110,2,0
1,1,0,-3.7,-2.7,0,WP2018,RANKL RANK signaling pathway,M110,2,0
1,1,0,-3.6,-2.2,0,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,M110,2,0
1,1,0,-2.5,-2.1,0,GO:0021700,developmental maturation,M110,2,0
1,0,1,-6,0,-2.9,M195,PID CMYB PATHWAY,M101,2,0
1,1,0,-2.6,-2.6,0,GO:0009855,determination of bilateral symmetry,M110,2,0
1,1,0,-3.6,-2.2,0,hsa04310,Wnt signaling pathway,M110,2,0
1,1,0,-3.2,-2.5,0,WP5198,Inflammatory bowel disease signaling,M110,2,0
1,1,0,-3.4,-2.1,0,GO:0051251,positive regulation of lymphocyte activation,M110,2,0
1,1,0,-3.4,-4.6,0,GO:0045619,regulation of lymphocyte differentiation,M110,2,0
1,1,0,-3.5,-6,0,GO:0035239,tube morphogenesis,M110,2,0
1,1,0,-4.7,-2.5,0,hsa05417,Lipid and atherosclerosis,M110,2,0
1,1,0,-5.8,-2.8,0,GO:0071396,cellular response to lipid,M110,2,0
1,0,1,-6.6,0,-3.7,GO:0006366,transcription by RNA polymerase II,M101,2,0
1,1,0,-3.1,-3.1,0,WP382,MAPK signaling pathway,M110,2,0
1,1,0,-2.7,-2.1,0,GO:0071331,cellular response to hexose stimulus,M110,2,0
1,1,0,-6.3,-4.6,0,GO:1902895,positive regulation of miRNA transcription,M110,2,0
1,1,0,-2.7,-2.1,0,GO:2000379,positive regulation of reactive oxygen species metabolic process,M110,2,0
1,1,0,-4,-2.5,0,GO:0071375,cellular response to peptide hormone stimulus,M110,2,0
1,1,0,-3.7,-2.8,0,GO:0048704,embryonic skeletal system morphogenesis,M110,2,0
1,1,0,-2.3,-2.9,0,GO:0043523,regulation of neuron apoptotic process,M110,2,0
1,1,0,-4,-3.4,0,hsa05166,Human T-cell leukemia virus 1 infection,M110,2,0
1,1,0,-6.7,-3.5,0,GO:0071363,cellular response to growth factor stimulus,M110,2,0
1,1,0,-2.1,-2.1,0,WP5144,NRP1 triggered signaling pathways in pancreatic cancer,M110,2,0
1,1,0,-6.1,-2,0,WP5293,Acute myeloid leukemia,M110,2,0
1,0,1,-2.8,0,-3.1,GO:0045600,positive regulation of fat cell differentiation,M101,2,0
1,1,0,-2.4,-2.1,0,GO:0022409,positive regulation of cell-cell adhesion,M110,2,0
1,1,0,-7,-2.1,0,GO:0002520,immune system development,M110,2,0
1,1,0,-2.6,-2.6,0,GO:0009799,specification of symmetry,M110,2,0
1,1,0,-3.4,-5.6,0,WP2840,Hair follicle development cytodifferentiation part 3 of 3,M110,2,0
1,1,0,-5.4,-2.9,0,WP2355,Corticotropin releasing hormone signaling pathway,M110,2,0
1,1,0,-4.5,-2.1,0,WP2882,Nuclear receptors meta pathway,M110,2,0
1,1,0,-3.8,-2.6,0,R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,M110,2,0
1,1,0,-2.2,-2.4,0,GO:0007548,sex differentiation,M110,2,0
1,1,0,-2.5,-3.1,0,WP2849,Hematopoietic stem cell differentiation,M110,2,0
1,1,0,-2.7,-2.8,0,GO:0048863,stem cell differentiation,M110,2,0
1,1,0,-5.3,-2.4,0,GO:1902894,negative regulation of miRNA transcription,M110,2,0
1,1,0,-2.5,-3.9,0,GO:0045621,positive regulation of lymphocyte differentiation,M110,2,0
1,1,0,-2.9,-2.2,0,GO:0009952,anterior/posterior pattern specification,M110,2,0
1,1,0,-3.9,-2.8,0,R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,M110,2,0
1,1,0,-3.3,-2.4,0,hsa04928,"Parathyroid hormone synthesis, secretion and action",M110,2,0
1,1,0,-2.7,-2.1,0,GO:0002292,T cell differentiation involved in immune response,M110,2,0
1,1,0,-7.9,-4.6,0,M167,PID AP1 PATHWAY,M110,2,0
1,1,0,-2.9,-4.8,0,GO:1903708,positive regulation of hemopoiesis,M110,2,0
1,1,0,-8,-2.2,0,WP4149,White fat cell differentiation,M110,2,0
1,1,0,-6.2,-2.1,0,GO:0042110,T cell activation,M110,2,0
1,1,0,-7.4,-3.1,0,GO:1903131,mononuclear cell differentiation,M110,2,0
1,1,0,-8.3,-4.1,0,GO:0009725,response to hormone,M110,2,0
1,1,0,-7.9,-3.7,0,GO:0010720,positive regulation of cell development,M110,2,0
1,1,0,-3.9,-3.6,0,M235,PID TCR CALCIUM PATHWAY,M110,2,0
1,1,0,-2.5,-3.9,0,GO:0001503,ossification,M110,2,0
1,1,0,-3.5,-2.5,0,hsa04010,MAPK signaling pathway,M110,2,0
1,1,0,-4.8,-2.3,0,GO:0043434,response to peptide hormone,M110,2,0
1,1,0,-3.9,-4.9,0,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M110,2,0
1,1,0,-8,-2.3,0,GO:0060322,head development,M110,2,0
1,1,0,-7.5,-3.3,0,GO:0045596,negative regulation of cell differentiation,M110,2,0
1,1,0,-3.9,-4.6,0,GO:0070670,response to interleukin-4,M110,2,0
1,1,0,-2.5,-2.1,0,WP4262,Breast cancer pathway,M110,2,0
1,1,0,-6.7,-3.9,0,GO:0001701,in utero embryonic development,M110,2,0
1,1,0,-2.3,-2.8,0,GO:0001825,blastocyst formation,M110,2,0
1,1,0,-4.1,-2.1,0,WP399,Wnt signaling pathway and pluripotency,M110,2,0
1,0,1,-5.8,0,-3.5,R-HSA-9616222,Transcriptional regulation of granulopoiesis,M101,2,0
1,1,0,-3.8,-2.3,0,GO:0040007,growth,M110,2,0
1,0,1,-2.1,0,-2.1,GO:0071695,anatomical structure maturation,M101,2,0
1,1,0,-3.4,-2.2,0,GO:0006954,inflammatory response,M110,2,0
1,1,0,-3,-2,0,WP428,Wnt signaling,M110,2,0
1,1,0,-5.8,-2.3,0,GO:1901699,cellular response to nitrogen compound,M110,2,0
1,1,0,-2,-3.5,0,GO:0061371,determination of heart left/right asymmetry,M110,2,0
1,1,0,-3.3,-4.3,0,GO:0007507,heart development,M110,2,0
1,1,0,-3.5,-5.2,0,GO:0045580,regulation of T cell differentiation,M110,2,0
1,1,0,-6.5,-2.2,0,GO:0019221,cytokine-mediated signaling pathway,M110,2,0
1,1,0,-3.5,-2.2,0,GO:0030900,forebrain development,M110,2,0
1,1,0,-5.3,-2.4,0,GO:2000629,negative regulation of miRNA metabolic process,M110,2,0
1,1,0,-9,-4.6,0,GO:0032870,cellular response to hormone stimulus,M110,2,0
1,1,0,-2.8,-2.2,0,GO:0002293,alpha-beta T cell differentiation involved in immune response,M110,2,0
1,1,0,-4.2,-2.7,0,GO:0050678,regulation of epithelial cell proliferation,M110,2,0
1,1,0,-6.6,-5,0,WP366,TGF beta signaling pathway,M110,2,0
1,1,0,-2.1,-2.6,0,GO:0048593,camera-type eye morphogenesis,M110,2,0
1,1,0,-3.5,-2.7,0,R-HSA-937061,TRIF(TICAM1)-mediated TLR4 signaling,M110,2,0
1,1,0,-5.4,-2.1,0,GO:0030217,T cell differentiation,M110,2,0
1,1,0,-8.8,-4.1,0,hsa05167,Kaposi sarcoma-associated herpesvirus infection,M110,2,0
1,1,0,-2.6,-5.3,0,GO:0061061,muscle structure development,M110,2,0
1,1,0,-6.3,-3.3,0,WP437,EGF EGFR signaling pathway,M110,2,0
1,1,0,-8.6,-2.4,0,WP706,Sudden infant death syndrome SIDS susceptibility pathways,M110,2,0
1,1,0,-2.9,-2.3,0,GO:0061458,reproductive system development,M110,2,0
1,1,0,-3.9,-3.6,0,hsa04658,Th1 and Th2 cell differentiation,M110,2,0
1,1,0,-4.9,-2.7,0,R-HSA-8939211,ESR-mediated signaling,M110,2,0
1,1,0,-2.4,-2.3,0,GO:1903039,positive regulation of leukocyte cell-cell adhesion,M110,2,0
1,1,0,-5.7,-4.1,0,GO:0001654,eye development,M110,2,0
1,1,0,-3.5,-2.2,0,GO:0030111,regulation of Wnt signaling pathway,M110,2,0
1,1,0,-4.5,-2,0,hsa05210,Colorectal cancer,M110,2,0
1,1,0,-9.7,-5.1,0,GO:0048732,gland development,M110,2,0
1,0,1,-4.9,0,-2.6,GO:0045444,fat cell differentiation,M101,2,0
1,1,0,-3.7,-5.6,0,GO:0002573,myeloid leukocyte differentiation,M110,2,0
1,1,0,-2.2,-5.2,0,GO:0035050,embryonic heart tube development,M110,2,0
1,0,1,-8,0,-4.1,GO:0045165,cell fate commitment,M101,2,0
0,1,1,0,-2,-3.2,GO:0051101,regulation of DNA binding,M011,2,0
1,1,0,-2.9,-6,0,GO:0030879,mammary gland development,M110,2,0
1,1,0,-2.2,-3.1,0,GO:0062012,regulation of small molecule metabolic process,M110,2,0
1,1,0,-2.1,-5.9,0,GO:0060021,roof of mouth development,M110,2,0
1,1,0,-3.8,-2.3,0,GO:0048589,developmental growth,M110,2,0
1,1,0,-2.3,-2.2,0,R-HSA-9679191,Potential therapeutics for SARS,M110,2,0
1,1,0,-8.5,-5.4,0,GO:0007423,sensory organ development,M110,2,0
1,1,0,-3.5,-3,0,GO:0022612,gland morphogenesis,M110,2,0
1,1,0,-7.7,-3.7,0,R-HSA-1280215,Cytokine Signaling in Immune system,M110,2,0
1,1,0,-5.9,-4,0,GO:0150063,visual system development,M110,2,0
1,0,1,-2.5,0,-2.1,GO:0051098,regulation of binding,M101,2,0
1,1,0,-4.6,-3.2,0,GO:0048706,embryonic skeletal system development,M110,2,0
1,1,0,-2.7,-2.1,0,GO:0071326,cellular response to monosaccharide stimulus,M110,2,0
1,1,0,-6.4,-4,0,R-HSA-198725,Nuclear Events (kinase and transcription factor activation),M110,2,0
1,1,0,-2.2,-2.2,0,GO:0071333,cellular response to glucose stimulus,M110,2,0
1,1,0,-2.8,-2.2,0,GO:0002287,alpha-beta T cell activation involved in immune response,M110,2,0
1,1,0,-5.9,-3,0,GO:1901652,response to peptide,M110,2,0
1,1,0,-5.2,-5.6,0,GO:1902105,regulation of leukocyte differentiation,M110,2,0
1,1,0,-2.6,-5.4,0,GO:0060485,mesenchyme development,M110,2,0
1,1,0,-5.4,-2.2,0,WP4155,Endometrial cancer,M110,2,0
1,1,0,-3.8,-3.6,0,GO:0001892,embryonic placenta development,M110,2,0
1,1,0,-4.3,-4.4,0,GO:0003002,regionalization,M110,2,0
1,1,0,-3,-2.4,0,GO:0007369,gastrulation,M110,2,0
1,1,0,-3.2,-2.9,0,GO:0071383,cellular response to steroid hormone stimulus,M110,2,0
1,1,0,-2,-3.1,0,M166,PID ATF2 PATHWAY,M110,2,0
1,1,0,-2.9,-2.3,0,GO:0048608,reproductive structure development,M110,2,0
1,1,0,-2.9,-2.4,0,M65,PID FRA PATHWAY,M110,2,0
1,1,0,-2.3,-4.1,0,M272,PID CD8 TCR DOWNSTREAM PATHWAY,M110,2,0
1,1,0,-6.5,-4.9,0,WP5130,Th17 cell differentiation pathway,M110,2,0
1,1,0,-4.3,-2.6,0,R-HSA-9018519,Estrogen-dependent gene expression,M110,2,0
1,1,0,-7.7,-3.7,0,hsa05161,Hepatitis B,M110,2,0
1,1,0,-5.6,-3.4,0,GO:1901653,cellular response to peptide,M110,2,0
1,1,0,-2.9,-2.2,0,WP5098,T cell activation SARS CoV 2,M110,2,0
1,1,0,-6.1,-7.2,0,GO:0048562,embryonic organ morphogenesis,M110,2,0
1,1,0,-4.6,-2.5,0,hsa04917,Prolactin signaling pathway,M110,2,0
1,1,0,-2.5,-2.2,0,GO:0048592,eye morphogenesis,M110,2,0
1,1,0,-8.1,-3.3,0,GO:0070848,response to growth factor,M110,2,0
1,0,1,-5.2,0,-2.3,GO:0001819,positive regulation of cytokine production,M101,2,0
1,1,0,-6.6,-3.4,0,R-HSA-166520,Signaling by NTRKs,M110,2,0
1,1,0,-2.4,-2.7,0,GO:1901655,cellular response to ketone,M110,2,0
1,1,0,-3,-2.7,0,GO:0007368,determination of left/right symmetry,M110,2,0
1,1,0,-6.1,-5.6,0,WP2857,Mesodermal commitment pathway,M110,2,0
1,1,0,-6.4,-2.4,0,GO:0071559,response to transforming growth factor beta,M110,2,0
1,1,0,-4.1,-2.7,0,GO:0071356,cellular response to tumor necrosis factor,M110,2,0
1,1,0,-3.2,-2.6,0,GO:0001678,intracellular glucose homeostasis,M110,2,0
1,0,1,-2,0,-3.5,GO:0061515,myeloid cell development,M101,2,0
1,1,0,-6.3,-4.1,0,R-HSA-449147,Signaling by Interleukins,M110,2,0
1,1,0,-5.4,-2.5,0,WP4630,Measles virus infection,M110,2,0
1,1,0,-2.2,-2.2,0,WP69,T cell receptor signaling pathway,M110,2,0
1,1,0,-2.8,-3.6,0,GO:0001890,placenta development,M110,2,0
1,1,0,-4.6,-3.1,0,GO:0048839,inner ear development,M110,2,0
1,1,0,-2.9,-4.5,0,WP1591,Heart development,M110,2,0
1,1,0,-3.9,-2.8,0,R-HSA-2990846,SUMOylation,M110,2,0
1,1,0,-5.7,-2.3,0,GO:0051249,regulation of lymphocyte activation,M110,2,0
1,1,0,-2.9,-4.8,0,GO:1902107,positive regulation of leukocyte differentiation,M110,2,0
1,1,0,-2.6,-4.3,0,GO:0045582,positive regulation of T cell differentiation,M110,2,0
1,1,0,-2.1,-3,0,GO:0098727,maintenance of cell number,M110,2,0
1,1,0,-5.6,-3.9,0,GO:0043010,camera-type eye development,M110,2,0
1,1,0,-2.3,-2.9,0,WP4239,Epithelial to mesenchymal transition in colorectal cancer,M110,2,0
1,1,0,-4.4,-3.3,0,R-HSA-525793,Myogenesis,M110,2,0
1,1,0,-7.1,-2.5,0,WP4659,Gastrin signaling pathway,M110,2,0
1,1,0,-3.5,-5.8,0,GO:0002009,morphogenesis of an epithelium,M110,2,0
1,1,0,-3.5,-7.8,0,GO:0048729,tissue morphogenesis,M110,2,0
1,1,0,-6.3,-4.3,0,GO:2000630,positive regulation of miRNA metabolic process,M110,2,0
1,1,0,-2.9,-2.4,0,GO:0010506,regulation of autophagy,M110,2,0
1,1,0,-2.1,-3.5,0,GO:0001947,heart looping,M110,2,0
1,1,0,-2.5,-2.2,0,hsa05224,Breast cancer,M110,2,0
1,0,1,-3.4,0,-2.7,GO:0072091,regulation of stem cell proliferation,M101,2,0
1,1,0,-4.7,-4.3,0,GO:0090596,sensory organ morphogenesis,M110,2,0
1,1,0,-3.6,-3.5,0,GO:0030851,granulocyte differentiation,M110,2,0
1,1,0,-2.8,-3,0,GO:0031667,response to nutrient levels,M110,2,0
1,1,0,-3.7,-2.6,0,R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,M110,2,0
1,1,0,-2.3,-2.7,0,WP5083,Neuroinflammation and glutamatergic signaling,M110,2,0
1,1,0,-5.8,-2.7,0,R-HSA-9006931,Signaling by Nuclear Receptors,M110,2,0
1,1,0,-3,-2.5,0,M229,PID P38 ALPHA BETA DOWNSTREAM PATHWAY,M110,2,0
1,1,0,-5.3,-2.4,0,WP1541,Energy metabolism,M110,2,0
1,1,0,-2.8,-2.1,0,GO:0046631,alpha-beta T cell activation,M110,2,0
1,1,0,-7,-2.7,0,hsa05200,Pathways in cancer,M110,2,0
1,1,0,-5.7,-2.4,0,GO:0071417,cellular response to organonitrogen compound,M110,2,0
1,1,0,-7,-4.8,0,WP2374,Oncostatin M signaling pathway,M110,2,0
1,1,0,-4.3,-3.5,0,M60,PID NFAT TFPATHWAY,M110,2,0
1,1,0,-3.6,-4.6,0,GO:0042472,inner ear morphogenesis,M110,2,0
1,1,0,-2.8,-5.4,0,GO:0060562,epithelial tube morphogenesis,M110,2,0
1,1,0,-2.1,-2.6,0,GO:1902075,cellular response to salt,M110,2,0
1,1,0,-3.5,-2.7,0,R-HSA-166166,MyD88-independent TLR4 cascade,M110,2,0
1,1,0,-3.6,-2.7,0,R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,M110,2,0
1,1,0,-4.9,-2.3,0,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M110,2,0
1,1,0,-2.7,-2.7,0,GO:0032350,regulation of hormone metabolic process,M110,2,0
1,1,0,-2.7,-2,0,GO:0048565,digestive tract development,M110,2,0
1,0,1,-5.1,0,-4.6,GO:0072089,stem cell proliferation,M101,2,0
1,1,0,-2.4,-4.9,0,GO:0007517,muscle organ development,M110,2,0
1,1,0,-2.3,-2.2,0,R-HSA-9758941,Gastrulation,M110,2,0
1,1,0,-2.8,-2.5,0,GO:0021543,pallium development,M110,2,0
1,1,0,-2.7,-3.2,0,WP4341,Non genomic actions of 1 25 dihydroxyvitamin D3,M110,2,0
1,1,0,-2.8,-3,0,GO:0030856,regulation of epithelial cell differentiation,M110,2,0
1,1,0,-2.2,-3.2,0,GO:0003143,embryonic heart tube morphogenesis,M110,2,0
1,1,0,-6.3,-2.1,0,hsa05221,Acute myeloid leukemia,M110,2,0
1,0,1,-3.3,0,-3.5,GO:0045646,regulation of erythrocyte differentiation,M101,2,0
1,1,0,-7.9,-3.9,0,WP4666,Hepatitis B infection,M110,2,0
1,1,0,-2.9,-3,0,WP3527,Pre implantation embryo,M110,2,0
1,1,0,-5.1,-3.5,0,hsa05235,PD-L1 expression and PD-1 checkpoint pathway in cancer,M110,2,0
1,1,0,-3.5,-3.9,0,GO:0048048,embryonic eye morphogenesis,M110,2,0
1,1,0,-2.8,-4.2,0,GO:0042471,ear morphogenesis,M110,2,0
1,1,0,-5.8,-4.9,0,hsa04380,Osteoclast differentiation,M110,2,0
1,1,0,-2.1,-2.1,0,WP4657,22q11 2 copy number variation syndrome,M110,2,0
1,1,0,-7.1,-2.5,0,GO:0007420,brain development,M110,2,0
1,1,0,-3.6,-2.4,0,GO:0030101,natural killer cell activation,M110,2,0
1,1,0,-3.6,-3.8,0,M115,PID REG GR PATHWAY,M110,2,0
1,1,0,-2.6,-2.8,0,GO:0009991,response to extracellular stimulus,M110,2,0
1,1,0,-2.9,-2.7,0,GO:0060972,left/right pattern formation,M110,2,0
1,1,0,-2.4,-3.9,0,GO:0001829,trophectodermal cell differentiation,M110,2,0
1,1,0,-3.7,-2.1,0,GO:0002761,regulation of myeloid leukocyte differentiation,M110,2,0
1,1,0,-2.1,-4.6,0,GO:0048596,embryonic camera-type eye morphogenesis,M110,2,0
1,1,0,-6.1,-3.3,0,R-HSA-9031628,NGF-stimulated transcription,M110,2,0
1,1,0,-2.9,-2.4,0,GO:0048545,response to steroid hormone,M110,2,0
1,1,0,-6.8,-3.6,0,R-HSA-187037,Signaling by NTRK1 (TRKA),M110,2,0
1,1,0,-5.8,-4,0,GO:0048880,sensory system development,M110,2,0
1,1,0,-4.7,-5.4,0,GO:0007389,pattern specification process,M110,2,0
1,1,0,-3.7,-2.8,0,GO:0043583,ear development,M110,2,0
1,1,0,-8.9,-4.2,0,M2,PID SMAD2 3NUCLEAR PATHWAY,M110,2,0
1,1,0,-7,-5.1,0,hsa04659,Th17 cell differentiation,M110,2,0
1,1,0,-4.1,-3.1,0,GO:0050863,regulation of T cell activation,M110,2,0
1,1,0,-7.8,-4.1,0,WP236,Adipogenesis,M110,2,0
1,1,0,-3.8,-2.6,0,R-HSA-975155,MyD88 dependent cascade initiated on endosome,M110,2,0
1,1,0,-5.4,-2.4,0,GO:0071560,cellular response to transforming growth factor beta stimulus,M110,2,0
1,1,0,-4.7,-2.9,0,WP2380,Brain derived neurotrophic factor BDNF signaling pathway,M110,2,0
1,1,0,-2.9,-3.3,0,WP5373,Role of hypoxia angiogenesis and FGF pathway in OA chondrocyte hypertrophy,M110,2,0
1,1,0,-3.6,-2.5,0,WP481,Insulin signaling,M110,2,0
1,1,0,-9,-4.4,0,GO:0071345,cellular response to cytokine stimulus,M110,2,0
1,1,0,-5.1,-2.2,0,hsa04218,Cellular senescence,M110,2,0
1,0,0,-2.5,0,0,GO:0120127,response to zinc ion starvation,M100,1,0
1,0,0,-3.4,0,0,GO:0032754,positive regulation of interleukin-5 production,M100,1,0
1,0,0,-3,0,0,GO:0021892,cerebral cortex GABAergic interneuron differentiation,M100,1,0
1,0,0,-2.6,0,0,WP53,ID signaling pathway,M100,1,0
1,0,0,-5,0,0,GO:0008285,negative regulation of cell population proliferation,M100,1,0
0,1,0,0,-5.2,0,GO:0048754,branching morphogenesis of an epithelial tube,M010,1,0
1,0,0,-2.9,0,0,M290,PID IL12 STAT4 PATHWAY,M100,1,0
1,0,0,-2.1,0,0,WP3640,Imatinib and chronic myeloid leukemia,M100,1,0
1,0,0,-4.5,0,0,WP170,Nuclear receptors,M100,1,0
1,0,0,-2.4,0,0,M113,PID NFAT 3PATHWAY,M100,1,0
1,0,0,-2.1,0,0,M196,PID IL23 PATHWAY,M100,1,0
1,0,0,-3,0,0,R-HSA-450294,MAP kinase activation,M100,1,0
1,0,0,-2.3,0,0,WP2203,Thymic stromal lymphopoietin TSLP signaling pathway,M100,1,0
1,0,0,-3.9,0,0,M175,PID ERBB2 ERBB3 PATHWAY,M100,1,0
1,0,0,-4.4,0,0,R-HSA-2871796,FCERI mediated MAPK activation,M100,1,0
1,0,0,-2.3,0,0,GO:0045773,positive regulation of axon extension,M100,1,0
1,0,0,-2.2,0,0,GO:0021537,telencephalon development,M100,1,0
1,0,0,-2.9,0,0,hsa04390,Hippo signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0002833,positive regulation of response to biotic stimulus,M100,1,0
1,0,0,-2.3,0,0,R-HSA-74158,RNA Polymerase III Transcription,M100,1,0
1,0,0,-3.6,0,0,GO:0010662,regulation of striated muscle cell apoptotic process,M100,1,0
1,0,0,-2.5,0,0,GO:0051250,negative regulation of lymphocyte activation,M100,1,0
1,0,0,-2.3,0,0,M71,PID ILK PATHWAY,M100,1,0
1,0,0,-2.4,0,0,R-HSA-9824443,Parasitic Infection Pathways,M100,1,0
1,0,0,-2.4,0,0,WP3630,NAD metabolism sirtuins and aging,M100,1,0
1,0,0,-2.3,0,0,GO:0014896,muscle hypertrophy,M100,1,0
0,1,0,0,-2.9,0,WP4830,GDNF RET signaling axis,M010,1,0
1,0,0,-2.6,0,0,R-HSA-1839117,Signaling by cytosolic FGFR1 fusion mutants,M100,1,0
1,0,0,-3.4,0,0,GO:0010464,regulation of mesenchymal cell proliferation,M100,1,0
1,0,0,-4.2,0,0,hsa04666,Fc gamma R-mediated phagocytosis,M100,1,0
1,0,0,-3,0,0,GO:0048617,embryonic foregut morphogenesis,M100,1,0
1,0,0,-4,0,0,R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,M100,1,0
1,0,0,-2.3,0,0,GO:0010665,regulation of cardiac muscle cell apoptotic process,M100,1,0
1,0,0,-2.1,0,0,GO:0097152,mesenchymal cell apoptotic process,M100,1,0
1,0,0,-2.4,0,0,GO:1904672,regulation of somatic stem cell population maintenance,M100,1,0
1,0,0,-6,0,0,GO:0009755,hormone-mediated signaling pathway,M100,1,0
0,1,0,0,-2.2,0,GO:0060840,artery development,M010,1,0
1,0,0,-2.1,0,0,R-HSA-9671555,Signaling by PDGFR in disease,M100,1,0
1,0,0,-2.1,0,0,GO:0060669,embryonic placenta morphogenesis,M100,1,0
1,0,0,-2.4,0,0,hsa04622,RIG-I-like receptor signaling pathway,M100,1,0
1,0,0,-5.4,0,0,WP2526,PDGF pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0001764,neuron migration,M100,1,0
1,0,0,-3.5,0,0,hsa05226,Gastric cancer,M100,1,0
1,0,0,-2.1,0,0,GO:0034139,regulation of toll-like receptor 3 signaling pathway,M100,1,0
1,0,0,-3.2,0,0,GO:0045686,negative regulation of glial cell differentiation,M100,1,0
1,0,0,-2.3,0,0,GO:0021872,forebrain generation of neurons,M100,1,0
1,0,0,-2.5,0,0,GO:0021546,rhombomere development,M100,1,0
0,1,0,0,-2.6,0,GO:0050870,positive regulation of T cell activation,M010,1,0
1,0,0,-2.6,0,0,WP49,IL 2 signaling pathway,M100,1,0
1,0,0,-3.4,0,0,WP1992,Genes targeted by miRNAs in adipocytes,M100,1,0
1,0,0,-2.9,0,0,GO:0048483,autonomic nervous system development,M100,1,0
1,0,0,-6.7,0,0,GO:0010001,glial cell differentiation,M100,1,0
1,0,0,-2.2,0,0,GO:0033077,T cell differentiation in thymus,M100,1,0
0,1,0,0,-4,0,GO:0048332,mesoderm morphogenesis,M010,1,0
0,1,0,0,-2.2,0,WP4331,Neovascularisation processes,M010,1,0
1,0,0,-2.2,0,0,R-HSA-5607764,CLEC7A (Dectin-1) signaling,M100,1,0
1,0,0,-3.8,0,0,WP1991,SRF and miRs in smooth muscle differentiation and proliferation,M100,1,0
1,0,0,-2.1,0,0,GO:0035265,organ growth,M100,1,0
0,1,0,0,-3,0,GO:0035162,embryonic hemopoiesis,M010,1,0
1,0,0,-2.2,0,0,GO:0050768,negative regulation of neurogenesis,M100,1,0
1,0,0,-2.5,0,0,GO:0007272,ensheathment of neurons,M100,1,0
0,1,0,0,-2.7,0,GO:0007565,female pregnancy,M010,1,0
1,0,0,-2.6,0,0,WP5316,Primary ovarian insufficiency,M100,1,0
1,0,0,-3.4,0,0,M32,PID HDAC CLASSIII PATHWAY,M100,1,0
1,0,0,-4,0,0,WP2263,Androgen receptor network in prostate cancer,M100,1,0
1,0,0,-3,0,0,R-HSA-381771,"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",M100,1,0
1,0,0,-2.4,0,0,WP4136,Fibrin complement receptor 3 signaling pathway,M100,1,0
1,0,0,-5.8,0,0,hsa04550,Signaling pathways regulating pluripotency of stem cells,M100,1,0
1,0,0,-3.2,0,0,GO:0050778,positive regulation of immune response,M100,1,0
1,0,0,-2.1,0,0,R-HSA-9006925,Intracellular signaling by second messengers,M100,1,0
1,0,0,-3,0,0,GO:0032747,positive regulation of interleukin-23 production,M100,1,0
1,0,0,-3.2,0,0,GO:0043254,regulation of protein-containing complex assembly,M100,1,0
1,0,0,-2.6,0,0,hsa04620,Toll-like receptor signaling pathway,M100,1,0
1,0,0,-5.3,0,0,R-HSA-4411364,Binding of TCF/LEF:CTNNB1 to target gene promoters,M100,1,0
1,0,0,-3.4,0,0,WP3594,Circadian rhythm genes,M100,1,0
0,1,0,0,-3.6,0,GO:0003205,cardiac chamber development,M010,1,0
0,1,0,0,-2.1,0,GO:0003176,aortic valve development,M010,1,0
1,0,0,-2.1,0,0,WP5174,Ulcerative colitis signaling,M100,1,0
1,0,0,-3.5,0,0,WP286,IL 3 signaling pathway,M100,1,0
1,0,0,-3.8,0,0,GO:0071236,cellular response to antibiotic,M100,1,0
1,0,0,-3.4,0,0,GO:2001054,negative regulation of mesenchymal cell apoptotic process,M100,1,0
1,0,0,-4.7,0,0,GO:0051962,positive regulation of nervous system development,M100,1,0
1,0,0,-2.3,0,0,GO:0002244,hematopoietic progenitor cell differentiation,M100,1,0
1,0,0,-2.4,0,0,GO:0048009,insulin-like growth factor receptor signaling pathway,M100,1,0
0,1,0,0,-3.3,0,GO:0001525,angiogenesis,M010,1,0
0,1,0,0,-5.1,0,GO:0072132,mesenchyme morphogenesis,M010,1,0
1,0,0,-3.5,0,0,GO:0045685,regulation of glial cell differentiation,M100,1,0
1,0,0,-2.5,0,0,WP1971,Integrated cancer pathway,M100,1,0
1,0,0,-2.2,0,0,R-HSA-9824446,Viral Infection Pathways,M100,1,0
1,0,0,-2.2,0,0,WP5087,Pleural mesothelioma,M100,1,0
1,0,0,-2.6,0,0,GO:2000106,regulation of leukocyte apoptotic process,M100,1,0
1,0,0,-5.2,0,0,R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,M100,1,0
1,0,0,-2.4,0,0,GO:0042113,B cell activation,M100,1,0
1,0,0,-2.3,0,0,R-HSA-3560783,"Defective B4GALT7 causes EDS, progeroid type",M100,1,0
1,0,0,-2.1,0,0,WP5102,Familial partial lipodystrophy,M100,1,0
1,0,0,-2.5,0,0,GO:0061008,hepaticobiliary system development,M100,1,0
1,0,0,-2.5,0,0,GO:0051147,regulation of muscle cell differentiation,M100,1,0
0,1,0,0,-2.9,0,GO:0003007,heart morphogenesis,M010,1,0
1,0,0,-2.3,0,0,GO:0070664,negative regulation of leukocyte proliferation,M100,1,0
0,1,0,0,-3.8,0,GO:0060561,apoptotic process involved in morphogenesis,M010,1,0
1,0,0,-3.4,0,0,GO:1990840,response to lectin,M100,1,0
1,0,0,-4.6,0,0,GO:0140467,integrated stress response signaling,M100,1,0
1,0,0,-2.3,0,0,GO:0010883,regulation of lipid storage,M100,1,0
1,0,0,-3.3,0,0,hsa05205,Proteoglycans in cancer,M100,1,0
1,0,0,-2.1,0,0,GO:0070555,response to interleukin-1,M100,1,0
1,0,0,-2.5,0,0,GO:0061035,regulation of cartilage development,M100,1,0
1,0,0,-2.6,0,0,GO:0060173,limb development,M100,1,0
1,0,0,-7.9,0,0,M183,PID IL6 7 PATHWAY,M100,1,0
0,1,0,0,-3.1,0,GO:0050886,endocrine process,M010,1,0
1,0,0,-2.6,0,0,WP5353,A network map of Macrophage stimulating protein MSP signaling,M100,1,0
1,0,0,-2.7,0,0,WP4205,MET in type 1 papillary renal cell carcinoma,M100,1,0
1,0,0,-4.7,0,0,R-HSA-8951430,RUNX3 regulates WNT signaling,M100,1,0
1,0,0,-2.3,0,0,GO:1903707,negative regulation of hemopoiesis,M100,1,0
0,1,0,0,-2.1,0,GO:0010038,response to metal ion,M010,1,0
1,0,0,-2.6,0,0,GO:0048736,appendage development,M100,1,0
1,0,0,-2.1,0,0,WP4685,Melanoma,M100,1,0
1,0,0,-2.6,0,0,WP4814,Somatic sex determination,M100,1,0
0,1,0,0,-2.2,0,M200,PID ERA GENOMIC PATHWAY,M010,1,0
1,0,0,-2,0,0,R-HSA-9006936,Signaling by TGFB family members,M100,1,0
1,0,0,-2.4,0,0,hsa04213,Longevity regulating pathway - multiple species,M100,1,0
1,0,0,-3.1,0,0,WP4481,Resistin as a regulator of inflammation,M100,1,0
1,0,0,-4.3,0,0,GO:0001818,negative regulation of cytokine production,M100,1,0
1,0,0,-2.4,0,0,R-HSA-9658195,Leishmania infection,M100,1,0
1,0,0,-4.1,0,0,M17200,SA B CELL RECEPTOR COMPLEXES,M100,1,0
1,0,0,-2.2,0,0,GO:1905330,regulation of morphogenesis of an epithelium,M100,1,0
1,0,0,-3.2,0,0,GO:0006325,chromatin organization,M100,1,0
1,0,0,-2.5,0,0,GO:0055123,digestive system development,M100,1,0
1,0,0,-2.3,0,0,M100,PID SHP2 PATHWAY,M100,1,0
0,1,0,0,-3.6,0,GO:0014823,response to activity,M010,1,0
1,0,0,-5.5,0,0,hsa05162,Measles,M100,1,0
1,0,0,-5.1,0,0,WP395,IL 4 signaling pathway,M100,1,0
1,0,0,-3.7,0,0,R-HSA-168898,Toll-like Receptor Cascades,M100,1,0
1,0,0,-5.7,0,0,GO:0030522,intracellular receptor signaling pathway,M100,1,0
0,1,0,0,-3,0,GO:0071277,cellular response to calcium ion,M010,1,0
1,0,0,-4.8,0,0,WP3888,VEGFA VEGFR2 signaling,M100,1,0
1,0,0,-4.2,0,0,GO:0120161,regulation of cold-induced thermogenesis,M100,1,0
1,0,0,-2.6,0,0,GO:0051092,positive regulation of NF-kappaB transcription factor activity,M100,1,0
1,0,0,-4.1,0,0,M288,PID HES HEY PATHWAY,M100,1,0
1,0,0,-3.2,0,0,GO:0014014,negative regulation of gliogenesis,M100,1,0
1,0,0,-2.9,0,0,GO:0043401,steroid hormone mediated signaling pathway,M100,1,0
0,1,0,0,-2.2,0,GO:0051592,response to calcium ion,M010,1,0
1,0,0,-3.5,0,0,hsa05207,Chemical carcinogenesis - receptor activation,M100,1,0
1,0,0,-2.1,0,0,R-HSA-3232118,SUMOylation of transcription factors,M100,1,0
1,0,0,-3.5,0,0,WP364,IL6 signaling pathway,M100,1,0
0,0,1,0,0,-2.4,GO:0009615,response to virus,M001,1,0
1,0,0,-2.4,0,0,WP422,MAPK cascade,M100,1,0
1,0,0,-2.6,0,0,GO:0048701,embryonic cranial skeleton morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0051961,negative regulation of nervous system development,M100,1,0
0,1,0,0,-2,0,GO:0048738,cardiac muscle tissue development,M010,1,0
1,0,0,-2.9,0,0,GO:0002294,"CD4-positive, alpha-beta T cell differentiation involved in immune response",M100,1,0
0,1,0,0,-3.5,0,GO:0003231,cardiac ventricle development,M010,1,0
1,0,0,-2.8,0,0,hsa05415,Diabetic cardiomyopathy,M100,1,0
1,0,0,-2,0,0,GO:0016331,morphogenesis of embryonic epithelium,M100,1,0
1,0,0,-4.5,0,0,hsa05220,Chronic myeloid leukemia,M100,1,0
1,0,0,-3.6,0,0,hsa04919,Thyroid hormone signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0007346,regulation of mitotic cell cycle,M100,1,0
0,1,0,0,-4.8,0,GO:0060443,mammary gland morphogenesis,M010,1,0
1,0,0,-2.7,0,0,GO:0140888,interferon-mediated signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0032715,negative regulation of interleukin-6 production,M100,1,0
1,0,0,-4.2,0,0,WP560,TGF beta receptor signaling,M100,1,0
1,0,0,-2.1,0,0,GO:0030500,regulation of bone mineralization,M100,1,0
1,0,0,-2.4,0,0,GO:0007159,leukocyte cell-cell adhesion,M100,1,0
1,0,0,-3.4,0,0,GO:0001502,cartilage condensation,M100,1,0
0,1,0,0,-2.4,0,GO:0060135,maternal process involved in female pregnancy,M010,1,0
1,0,0,-2.5,0,0,hsa05133,Pertussis,M100,1,0
0,1,0,0,-3.1,0,GO:0060603,mammary gland duct morphogenesis,M010,1,0
1,0,0,-2.6,0,0,GO:0030323,respiratory tube development,M100,1,0
1,0,0,-2.9,0,0,GO:0016049,cell growth,M100,1,0
1,0,0,-3.7,0,0,GO:1903037,regulation of leukocyte cell-cell adhesion,M100,1,0
1,0,0,-3.5,0,0,GO:0120162,positive regulation of cold-induced thermogenesis,M100,1,0
1,0,0,-3.1,0,0,R-HSA-9701898,STAT3 nuclear events downstream of ALK signaling,M100,1,0
1,0,0,-5.6,0,0,GO:0050727,regulation of inflammatory response,M100,1,0
1,0,0,-3.6,0,0,M45,PID CD40 PATHWAY,M100,1,0
1,0,0,-2.8,0,0,WP2877,Vitamin D receptor pathway,M100,1,0
1,0,0,-2.6,0,0,hsa04912,GnRH signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0048664,neuron fate determination,M100,1,0
1,0,0,-2.1,0,0,GO:0001838,embryonic epithelial tube formation,M100,1,0
1,0,0,-3.1,0,0,R-HSA-9674555,Signaling by CSF3 (G-CSF),M100,1,0
1,0,0,-3.1,0,0,GO:0048511,rhythmic process,M100,1,0
1,0,0,-2.4,0,0,WP4871,Kisspeptin kisspeptin receptor system in the ovary,M100,1,0
0,1,0,0,-2.2,0,WP4674,Head and neck squamous cell carcinoma,M010,1,0
1,0,0,-2.3,0,0,GO:0090497,mesenchymal cell migration,M100,1,0
1,0,0,-4.5,0,0,GO:0062207,regulation of pattern recognition receptor signaling pathway,M100,1,0
1,0,0,-2.6,0,0,GO:0007440,foregut morphogenesis,M100,1,0
1,0,0,-2.8,0,0,GO:0031348,negative regulation of defense response,M100,1,0
1,0,0,-2.4,0,0,GO:0060074,synapse maturation,M100,1,0
0,1,0,0,-2.4,0,GO:0071248,cellular response to metal ion,M010,1,0
1,0,0,-6,0,0,GO:0071407,cellular response to organic cyclic compound,M100,1,0
1,0,0,-3.3,0,0,GO:1905332,positive regulation of morphogenesis of an epithelium,M100,1,0
1,0,0,-2.5,0,0,GO:0071772,response to BMP,M100,1,0
1,0,0,-3,0,0,GO:0002250,adaptive immune response,M100,1,0
1,0,0,-2.4,0,0,GO:0021783,preganglionic parasympathetic fiber development,M100,1,0
1,0,0,-3.4,0,0,GO:0046632,alpha-beta T cell differentiation,M100,1,0
1,0,0,-3.2,0,0,GO:0033500,carbohydrate homeostasis,M100,1,0
1,0,0,-2.1,0,0,GO:1901535,regulation of DNA demethylation,M100,1,0
1,0,0,-2.4,0,0,GO:0010453,regulation of cell fate commitment,M100,1,0
1,0,0,-3.3,0,0,GO:0002052,positive regulation of neuroblast proliferation,M100,1,0
1,0,0,-2.1,0,0,GO:0043368,positive T cell selection,M100,1,0
1,0,0,-2.9,0,0,GO:0002066,columnar/cuboidal epithelial cell development,M100,1,0
1,0,0,-4,0,0,R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,M100,1,0
1,0,0,-3,0,0,M213,PID AR NONGENOMIC PATHWAY,M100,1,0
1,0,0,-2.2,0,0,R-HSA-4839726,Chromatin organization,M100,1,0
1,0,0,-2.6,0,0,GO:0048645,animal organ formation,M100,1,0
1,0,0,-2.1,0,0,GO:0006991,response to sterol depletion,M100,1,0
1,0,0,-2.7,0,0,R-HSA-201681,TCF dependent signaling in response to WNT,M100,1,0
1,0,0,-2.1,0,0,CORUM:3234,"SMAD2-SMAD4-FAST1-TGIF-HDAC1 complex, TGF(beta) induced",M100,1,0
1,0,0,-3.4,0,0,GO:0032674,regulation of interleukin-5 production,M100,1,0
1,0,0,-2.6,0,0,M161,PID IFNG PATHWAY,M100,1,0
1,0,0,-3,0,0,R-HSA-9733709,Cardiogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0043433,negative regulation of DNA-binding transcription factor activity,M100,1,0
1,0,0,-2.7,0,0,hsa05231,Choline metabolism in cancer,M100,1,0
0,1,0,0,-4,0,GO:0003206,cardiac chamber morphogenesis,M010,1,0
1,0,0,-2.2,0,0,GO:0007610,behavior,M100,1,0
0,1,0,0,-3.8,0,GO:0042594,response to starvation,M010,1,0
0,0,1,0,0,-2.4,GO:0050729,positive regulation of inflammatory response,M001,1,0
1,0,0,-2.4,0,0,GO:0050866,negative regulation of cell activation,M100,1,0
1,0,0,-2.2,0,0,GO:0002757,immune response-activating signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0002285,lymphocyte activation involved in immune response,M100,1,0
1,0,0,-3.2,0,0,M40,PID E2F PATHWAY,M100,1,0
1,0,0,-3,0,0,CORUM:2694,ERG-JUN-FOS DNA-protein complex,M100,1,0
0,1,0,0,-4.7,0,GO:0001837,epithelial to mesenchymal transition,M010,1,0
1,0,0,-5.4,0,0,M10,PID BCR 5PATHWAY,M100,1,0
1,0,0,-2.6,0,0,R-HSA-9006335,Signaling by Erythropoietin,M100,1,0
1,0,0,-3.7,0,0,hsa04630,JAK-STAT signaling pathway,M100,1,0
1,0,0,-4.1,0,0,GO:0002065,columnar/cuboidal epithelial cell differentiation,M100,1,0
1,0,0,-2.3,0,0,GO:0022407,regulation of cell-cell adhesion,M100,1,0
1,0,0,-3.2,0,0,M162,PID RXR VDR PATHWAY,M100,1,0
1,0,0,-3.1,0,0,GO:0032481,positive regulation of type I interferon production,M100,1,0
1,0,0,-4.8,0,0,GO:0002062,chondrocyte differentiation,M100,1,0
0,1,0,0,-2.6,0,GO:0051150,regulation of smooth muscle cell differentiation,M010,1,0
0,1,0,0,-2.4,0,GO:0071384,cellular response to corticosteroid stimulus,M010,1,0
1,0,0,-6.8,0,0,GO:0042063,gliogenesis,M100,1,0
1,0,0,-2.9,0,0,GO:0002262,myeloid cell homeostasis,M100,1,0
1,0,0,-2.3,0,0,GO:0030183,B cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0046626,regulation of insulin receptor signaling pathway,M100,1,0
1,0,0,-2.5,0,0,hsa05165,Human papillomavirus infection,M100,1,0
1,0,0,-2.1,0,0,R-HSA-452723,Transcriptional regulation of pluripotent stem cells,M100,1,0
1,0,0,-3.4,0,0,GO:0098743,cell aggregation,M100,1,0
1,0,0,-5.2,0,0,R-HSA-5619507,Activation of HOX genes during differentiation,M100,1,0
1,0,0,-3.6,0,0,WP5072,Modulators of TCR signaling and T cell activation,M100,1,0
1,0,0,-3,0,0,WP3981,miRNA regulation of prostate cancer signaling pathways,M100,1,0
1,0,0,-5.1,0,0,hsa04625,C-type lectin receptor signaling pathway,M100,1,0
1,0,0,-2.9,0,0,GO:2001053,regulation of mesenchymal cell apoptotic process,M100,1,0
1,0,0,-2.9,0,0,M254,PID MYC REPRESS PATHWAY,M100,1,0
1,0,0,-2,0,0,hsa04750,Inflammatory mediator regulation of TRP channels,M100,1,0
1,0,0,-2.6,0,0,GO:0030850,prostate gland development,M100,1,0
0,1,0,0,-3.8,0,GO:0001568,blood vessel development,M010,1,0
1,0,0,-2.2,0,0,GO:1903320,regulation of protein modification by small protein conjugation or removal,M100,1,0
1,0,0,-3.8,0,0,WP138,Androgen receptor signaling pathway,M100,1,0
0,1,0,0,-2,0,GO:0055092,sterol homeostasis,M010,1,0
1,0,0,-3.1,0,0,GO:0032103,positive regulation of response to external stimulus,M100,1,0
1,0,0,-2.1,0,0,GO:0060575,intestinal epithelial cell differentiation,M100,1,0
1,0,0,-2.2,0,0,WP1544,MicroRNAs in cardiomyocyte hypertrophy,M100,1,0
1,0,0,-2,0,0,WP2118,Arrhythmogenic right ventricular cardiomyopathy,M100,1,0
1,0,0,-2.1,0,0,M110,PID IL1 PATHWAY,M100,1,0
1,0,0,-3.5,0,0,GO:0002696,positive regulation of leukocyte activation,M100,1,0
1,0,0,-4.7,0,0,GO:0009743,response to carbohydrate,M100,1,0
1,0,0,-4,0,0,hsa04012,ErbB signaling pathway,M100,1,0
1,0,0,-5.5,0,0,GO:0048709,oligodendrocyte differentiation,M100,1,0
1,0,0,-2.8,0,0,hsa05016,Huntington disease,M100,1,0
1,0,0,-2.1,0,0,R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,M100,1,0
1,0,0,-3.1,0,0,GO:0009749,response to glucose,M100,1,0
1,0,0,-2.1,0,0,WP75,Toll like receptor signaling pathway,M100,1,0
1,0,0,-3.3,0,0,R-HSA-4090294,SUMOylation of intracellular receptors,M100,1,0
1,0,0,-3,0,0,CORUM:2695,ETS2-FOS-JUN complex,M100,1,0
1,0,0,-2.1,0,0,GO:0010225,response to UV-C,M100,1,0
0,1,0,0,-2.9,0,GO:1902742,apoptotic process involved in development,M010,1,0
0,1,0,0,-2.2,0,GO:0071241,cellular response to inorganic substance,M010,1,0
1,0,0,-2.6,0,0,GO:0002263,cell activation involved in immune response,M100,1,0
1,0,0,-3.5,0,0,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M100,1,0
1,0,0,-2.1,0,0,GO:1903038,negative regulation of leukocyte cell-cell adhesion,M100,1,0
1,0,0,-2,0,0,GO:0001706,endoderm formation,M100,1,0
1,0,0,-2.1,0,0,WP4880,Host pathogen interaction of human coronaviruses interferon induction,M100,1,0
1,0,0,-2.7,0,0,WP3414,Initiation of transcription and translation elongation at the HIV 1 LTR,M100,1,0
0,1,0,0,-2.6,0,GO:0048844,artery morphogenesis,M010,1,0
1,0,0,-2.4,0,0,GO:0045648,positive regulation of erythrocyte differentiation,M100,1,0
0,1,0,0,-2.2,0,GO:0071496,cellular response to external stimulus,M010,1,0
1,0,0,-2.5,0,0,GO:0044089,positive regulation of cellular component biogenesis,M100,1,0
0,1,0,0,-2.4,0,GO:0044706,multi-multicellular organism process,M010,1,0
1,0,0,-2.4,0,0,GO:0042752,regulation of circadian rhythm,M100,1,0
1,0,0,-6.3,0,0,R-HSA-2262752,Cellular responses to stress,M100,1,0
1,0,0,-4.1,0,0,hsa05418,Fluid shear stress and atherosclerosis,M100,1,0
1,0,0,-3,0,0,WP3915,Angiopoietin like protein 8 regulatory pathway,M100,1,0
1,0,0,-3.5,0,0,hsa04350,TGF-beta signaling pathway,M100,1,0
1,0,0,-4,0,0,R-HSA-3769402,Deactivation of the beta-catenin transactivating complex,M100,1,0
1,0,0,-3.3,0,0,M151,PID AR TF PATHWAY,M100,1,0
1,0,0,-4.4,0,0,GO:0021781,glial cell fate commitment,M100,1,0
1,0,0,-2.1,0,0,GO:0097154,GABAergic neuron differentiation,M100,1,0
1,0,0,-2.7,0,0,GO:2000179,positive regulation of neural precursor cell proliferation,M100,1,0
1,0,0,-2.5,0,0,GO:0045722,positive regulation of gluconeogenesis,M100,1,0
1,0,0,-2.3,0,0,GO:0048486,parasympathetic nervous system development,M100,1,0
0,1,0,0,-3,0,WP3858,Toll like receptor signaling related to MyD88,M010,1,0
1,0,0,-3.2,0,0,R-HSA-109582,Hemostasis,M100,1,0
1,0,0,-2.3,0,0,GO:0001755,neural crest cell migration,M100,1,0
1,0,0,-2.4,0,0,R-HSA-9670439,"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",M100,1,0
1,0,0,-3.4,0,0,GO:0061351,neural precursor cell proliferation,M100,1,0
1,0,0,-3.4,0,0,WP4258,lncRNA in canonical Wnt signaling and colorectal cancer,M100,1,0
0,1,0,0,-2,0,GO:0016358,dendrite development,M010,1,0
1,0,0,-2.5,0,0,R-HSA-5621480,Dectin-2 family,M100,1,0
0,1,0,0,-2.8,0,GO:0007498,mesoderm development,M010,1,0
1,0,0,-3.5,0,0,GO:0071219,cellular response to molecule of bacterial origin,M100,1,0
1,0,0,-2.6,0,0,WP3932,Focal adhesion PI3K Akt mTOR signaling pathway,M100,1,0
1,0,0,-3.5,0,0,GO:0009746,response to hexose,M100,1,0
1,0,0,-2.7,0,0,R-HSA-4086398,Ca2+ pathway,M100,1,0
1,0,0,-2.4,0,0,hsa05223,Non-small cell lung cancer,M100,1,0
1,0,0,-2.2,0,0,GO:0002253,activation of immune response,M100,1,0
1,0,0,-2.4,0,0,GO:2000647,negative regulation of stem cell proliferation,M100,1,0
1,0,0,-2.6,0,0,WP391,Mitochondrial gene expression,M100,1,0
1,0,0,-4.2,0,0,hsa04662,B cell receptor signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0014074,response to purine-containing compound,M100,1,0
1,0,0,-4.2,0,0,GO:0045664,regulation of neuron differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0060534,trachea cartilage development,M100,1,0
1,0,0,-2.1,0,0,GO:0030902,hindbrain development,M100,1,0
1,0,0,-2.4,0,0,GO:0140718,facultative heterochromatin formation,M100,1,0
0,1,0,0,-3.3,0,GO:0009914,hormone transport,M010,1,0
1,0,0,-2.1,0,0,GO:0002088,lens development in camera-type eye,M100,1,0
1,0,0,-2.7,0,0,R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,M100,1,0
0,1,0,0,-3.2,0,M54,PID IL12 2PATHWAY,M010,1,0
1,0,0,-2.6,0,0,GO:0060037,pharyngeal system development,M100,1,0
1,0,0,-3.4,0,0,GO:0007167,enzyme-linked receptor protein signaling pathway,M100,1,0
0,1,0,0,-2.2,0,GO:0035113,embryonic appendage morphogenesis,M010,1,0
0,1,0,0,-2.2,0,GO:0071456,cellular response to hypoxia,M010,1,0
0,1,0,0,-2,0,GO:0030178,negative regulation of Wnt signaling pathway,M010,1,0
1,0,0,-2.9,0,0,WP195,IL 1 signaling pathway,M100,1,0
1,0,0,-3.8,0,0,M186,PID PDGFRB PATHWAY,M100,1,0
1,0,0,-5.4,0,0,GO:0051960,regulation of nervous system development,M100,1,0
1,0,0,-3.5,0,0,M28,PID IL4 2PATHWAY,M100,1,0
1,0,0,-2,0,0,GO:0031331,positive regulation of cellular catabolic process,M100,1,0
1,0,0,-2.9,0,0,R-HSA-6807505,RNA polymerase II transcribes snRNA genes,M100,1,0
1,0,0,-4.4,0,0,M105,PID TELOMERASE PATHWAY,M100,1,0
1,0,0,-5.6,0,0,hsa05203,Viral carcinogenesis,M100,1,0
1,0,0,-2.7,0,0,GO:0045089,positive regulation of innate immune response,M100,1,0
1,0,0,-2,0,0,WP5352,10q11 21q11 23 copy number variation syndrome,M100,1,0
1,0,0,-2.4,0,0,CORUM:5614,Emerin complex 32,M100,1,0
1,0,0,-2.8,0,0,GO:0045087,innate immune response,M100,1,0
1,0,0,-2.8,0,0,WP2864,Apoptosis related network due to altered Notch3 in ovarian cancer,M100,1,0
0,1,0,0,-4.6,0,GO:0061138,morphogenesis of a branching epithelium,M010,1,0
1,0,0,-3.6,0,0,R-HSA-448424,Interleukin-17 signaling,M100,1,0
1,0,0,-2.5,0,0,GO:0032094,response to food,M100,1,0
1,0,0,-2.3,0,0,R-HSA-749476,RNA Polymerase III Abortive And Retractive Initiation,M100,1,0
1,0,0,-2.2,0,0,hsa04060,Cytokine-cytokine receptor interaction,M100,1,0
1,0,0,-3.9,0,0,hsa04936,Alcoholic liver disease,M100,1,0
1,0,0,-3.2,0,0,hsa04660,T cell receptor signaling pathway,M100,1,0
1,0,0,-3.1,0,0,M12,PID RHOA PATHWAY,M100,1,0
1,0,0,-2.1,0,0,R-HSA-1059683,Interleukin-6 signaling,M100,1,0
1,0,0,-4.8,0,0,WP2324,AGE RAGE pathway,M100,1,0
1,0,0,-2.6,0,0,R-HSA-1989781,PPARA activates gene expression,M100,1,0
1,0,0,-2.1,0,0,GO:0060251,regulation of glial cell proliferation,M100,1,0
0,1,0,0,-2.5,0,WP5115,Network map of SARS CoV 2 signaling pathway,M010,1,0
1,0,0,-2,0,0,GO:1903321,negative regulation of protein modification by small protein conjugation or removal,M100,1,0
1,0,0,-2.1,0,0,GO:0046677,response to antibiotic,M100,1,0
0,1,0,0,-3.2,0,GO:0009267,cellular response to starvation,M010,1,0
1,0,0,-2.8,0,0,hsa04722,Neurotrophin signaling pathway,M100,1,0
1,0,0,-2.4,0,0,hsa05135,Yersinia infection,M100,1,0
1,0,0,-5.2,0,0,GO:0050769,positive regulation of neurogenesis,M100,1,0
1,0,0,-2.7,0,0,WP3929,Chemokine signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0048477,oogenesis,M100,1,0
1,0,0,-4.8,0,0,WP4844,Influence of laminopathies on Wnt signaling,M100,1,0
1,0,0,-3.1,0,0,GO:0050670,regulation of lymphocyte proliferation,M100,1,0
1,0,0,-3,0,0,hsa05170,Human immunodeficiency virus 1 infection,M100,1,0
1,0,0,-2.3,0,0,GO:0090335,regulation of brown fat cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0031016,pancreas development,M100,1,0
0,1,0,0,-4.4,0,GO:0001763,morphogenesis of a branching structure,M010,1,0
1,0,0,-2.1,0,0,WP4496,Signal transduction through IL1R,M100,1,0
1,0,0,-2.3,0,0,GO:0009994,oocyte differentiation,M100,1,0
1,0,0,-2.3,0,0,GO:0032259,methylation,M100,1,0
1,0,0,-3.6,0,0,M122,PID IL2 1PATHWAY,M100,1,0
1,0,0,-3.4,0,0,GO:0060396,growth hormone receptor signaling pathway,M100,1,0
1,0,0,-3.3,0,0,GO:0034284,response to monosaccharide,M100,1,0
1,0,0,-2.5,0,0,GO:0032330,regulation of chondrocyte differentiation,M100,1,0
1,0,0,-2.4,0,0,GO:0035994,response to muscle stretch,M100,1,0
0,1,0,0,-2.2,0,GO:0016055,Wnt signaling pathway,M010,1,0
1,0,0,-4.9,0,0,hsa05163,Human cytomegalovirus infection,M100,1,0
1,0,0,-2.8,0,0,GO:0045669,positive regulation of osteoblast differentiation,M100,1,0
1,0,0,-2.3,0,0,R-HSA-202733,Cell surface interactions at the vascular wall,M100,1,0
1,0,0,-4.9,0,0,WP127,IL 5 signaling pathway,M100,1,0
0,1,0,0,-2,0,GO:0003197,endocardial cushion development,M010,1,0
1,0,0,-2.6,0,0,GO:0045058,T cell selection,M100,1,0
1,0,0,-2.5,0,0,GO:0008366,axon ensheathment,M100,1,0
1,0,0,-2.5,0,0,GO:0070432,regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway,M100,1,0
1,0,0,-2.6,0,0,R-HSA-6783589,Interleukin-6 family signaling,M100,1,0
1,0,0,-2.9,0,0,GO:0032869,cellular response to insulin stimulus,M100,1,0
0,1,0,0,-2.1,0,GO:0050810,regulation of steroid biosynthetic process,M010,1,0
1,0,0,-2.5,0,0,GO:0061760,antifungal innate immune response,M100,1,0
1,0,0,-7.5,0,0,GO:0051216,cartilage development,M100,1,0
0,0,1,0,0,-2.7,GO:0001708,cell fate specification,M001,1,0
1,0,0,-3.4,0,0,GO:0034143,regulation of toll-like receptor 4 signaling pathway,M100,1,0
1,0,0,-2.1,0,0,WP4320,Effect of progerin on genes involved in Hutchinson Gilford progeria syndrome,M100,1,0
1,0,0,-2.3,0,0,WP3863,T cell antigen receptor TCR pathway during Staphylococcus aureus infection,M100,1,0
1,0,0,-2.3,0,0,GO:0001659,temperature homeostasis,M100,1,0
0,0,1,0,0,-2.5,GO:0043524,negative regulation of neuron apoptotic process,M001,1,0
1,0,0,-2.5,0,0,hsa04022,cGMP-PKG signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0009617,response to bacterium,M100,1,0
1,0,0,-3,0,0,R-HSA-2871809,FCERI mediated Ca+2 mobilization,M100,1,0
0,1,0,0,-5.1,0,GO:0048341,paraxial mesoderm formation,M010,1,0
1,0,0,-2.6,0,0,R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,M100,1,0
1,0,0,-2.1,0,0,GO:0061550,cranial ganglion development,M100,1,0
1,0,0,-3.3,0,0,GO:0045785,positive regulation of cell adhesion,M100,1,0
1,0,0,-5.4,0,0,hsa05169,Epstein-Barr virus infection,M100,1,0
0,1,0,0,-2.2,0,GO:0030326,embryonic limb morphogenesis,M010,1,0
1,0,0,-2.5,0,0,WP5417,Cell lineage map for neuronal differentiation,M100,1,0
1,0,0,-2.3,0,0,R-HSA-4420332,Defective B3GALT6 causes EDSP2 and SEMDJL1,M100,1,0
1,0,0,-2.3,0,0,GO:0046580,negative regulation of Ras protein signal transduction,M100,1,0
1,0,0,-3.6,0,0,GO:0070663,regulation of leukocyte proliferation,M100,1,0
1,0,0,-4.4,0,0,WP2858,Ectoderm differentiation,M100,1,0
0,1,0,0,-2,0,GO:1905314,semi-lunar valve development,M010,1,0
1,0,0,-3.1,0,0,M182,PID IL3 PATHWAY,M100,1,0
1,0,0,-6.9,0,0,WP3972,PDGFR beta pathway,M100,1,0
1,0,0,-3.2,0,0,R-HSA-195721,Signaling by WNT,M100,1,0
1,0,0,-2.7,0,0,GO:1902692,regulation of neuroblast proliferation,M100,1,0
1,0,0,-2.2,0,0,GO:0048667,cell morphogenesis involved in neuron differentiation,M100,1,0
1,0,0,-2.6,0,0,R-HSA-201556,Signaling by ALK,M100,1,0
1,0,0,-2.1,0,0,GO:0021903,rostrocaudal neural tube patterning,M100,1,0
1,0,0,-3.6,0,0,WP2037,Prolactin signaling pathway,M100,1,0
1,0,0,-6.4,0,0,hsa05215,Prostate cancer,M100,1,0
1,0,0,-3.9,0,0,R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,M100,1,0
1,0,0,-2.4,0,0,GO:0001656,metanephros development,M100,1,0
1,0,0,-3.6,0,0,GO:0043586,tongue development,M100,1,0
1,0,0,-4.4,0,0,M63,PID AVB3 OPN PATHWAY,M100,1,0
1,0,0,-3,0,0,CORUM:2693,NFAT-JUN-FOS DNA-protein complex,M100,1,0
1,0,0,-2.6,0,0,GO:0070486,leukocyte aggregation,M100,1,0
1,0,0,-2.4,0,0,GO:2001014,regulation of skeletal muscle cell differentiation,M100,1,0
1,0,0,-2.1,0,0,WP3865,Novel intracellular components of RIG I like receptor pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0010664,negative regulation of striated muscle cell apoptotic process,M100,1,0
0,1,0,0,-2,0,GO:0043536,positive regulation of blood vessel endothelial cell migration,M010,1,0
0,1,0,0,-2.3,0,GO:0072163,mesonephric epithelium development,M010,1,0
1,0,0,-2.6,0,0,GO:2001243,negative regulation of intrinsic apoptotic signaling pathway,M100,1,0
0,1,0,0,-2.2,0,WP4823,Genes controlling nephrogenesis,M010,1,0
1,0,0,-3.4,0,0,WP4928,MAPK pathway in congenital thyroid cancer,M100,1,0
1,0,0,-3.3,0,0,GO:0071222,cellular response to lipopolysaccharide,M100,1,0
1,0,0,-3.3,0,0,GO:0048538,thymus development,M100,1,0
1,0,0,-2.1,0,0,GO:2000378,negative regulation of reactive oxygen species metabolic process,M100,1,0
1,0,0,-5.3,0,0,M26,PID NFKAPPAB ATYPICAL PATHWAY,M100,1,0
1,0,0,-3.3,0,0,GO:0032496,response to lipopolysaccharide,M100,1,0
0,1,0,0,-4.6,0,GO:0006984,ER-nucleus signaling pathway,M010,1,0
1,0,0,-2.9,0,0,GO:0002683,negative regulation of immune system process,M100,1,0
0,1,0,0,-2.1,0,GO:0072009,nephron epithelium development,M010,1,0
1,0,0,-2.2,0,0,R-HSA-3247509,Chromatin modifying enzymes,M100,1,0
1,0,0,-2.1,0,0,GO:0061197,fungiform papilla morphogenesis,M100,1,0
1,0,0,-2.9,0,0,hsa04062,Chemokine signaling pathway,M100,1,0
1,0,0,-4.7,0,0,WP673,ErbB signaling pathway,M100,1,0
1,0,0,-2.5,0,0,GO:0060710,chorio-allantoic fusion,M100,1,0
0,1,0,0,-2.8,0,GO:0060070,canonical Wnt signaling pathway,M010,1,0
1,0,0,-2.3,0,0,GO:0006109,regulation of carbohydrate metabolic process,M100,1,0
0,1,0,0,-2,0,GO:0008203,cholesterol metabolic process,M010,1,0
1,0,0,-3.8,0,0,hsa05225,Hepatocellular carcinoma,M100,1,0
1,0,0,-2.3,0,0,R-HSA-2559585,Oncogene Induced Senescence,M100,1,0
1,0,0,-3.6,0,0,WP2023,Cell differentiation expanded index,M100,1,0
0,1,0,0,-2.2,0,GO:0198738,cell-cell signaling by wnt,M010,1,0
1,0,0,-2.6,0,0,M193,PID NEPHRIN NEPH1 PATHWAY,M100,1,0
1,0,0,-2.9,0,0,GO:2001234,negative regulation of apoptotic signaling pathway,M100,1,0
1,0,0,-3,0,0,GO:1902869,regulation of amacrine cell differentiation,M100,1,0
1,0,0,-3.1,0,0,GO:0021545,cranial nerve development,M100,1,0
1,0,0,-3.4,0,0,M164,PID ERBB1 DOWNSTREAM PATHWAY,M100,1,0
1,0,0,-2.6,0,0,WP4304,Oligodendrocyte specification and differentiation leading to myelin components for CNS,M100,1,0
1,0,0,-2.7,0,0,WP410,Exercise induced circadian regulation,M100,1,0
1,0,0,-2.3,0,0,R-HSA-5621481,C-type lectin receptors (CLRs),M100,1,0
1,0,0,-3.4,0,0,R-HSA-9823730,Formation of definitive endoderm,M100,1,0
0,1,0,0,-3,0,WP5036,Angiotensin II receptor type 1 pathway,M010,1,0
0,1,0,0,-2.3,0,GO:0007219,Notch signaling pathway,M010,1,0
1,0,0,-3,0,0,GO:0051176,positive regulation of sulfur metabolic process,M100,1,0
0,1,0,0,-2.2,0,GO:0019827,stem cell population maintenance,M010,1,0
1,0,0,-3.5,0,0,WP4538,Regulatory circuits of the STAT3 signaling pathway,M100,1,0
1,0,0,-3.4,0,0,GO:1990858,cellular response to lectin,M100,1,0
1,0,0,-2.6,0,0,GO:0060416,response to growth hormone,M100,1,0
1,0,0,-2.6,0,0,WP2011,SREBF and miR33 in cholesterol and lipid homeostasis,M100,1,0
1,0,0,-2.9,0,0,R-HSA-9725371,Nuclear events stimulated by ALK signaling in cancer,M100,1,0
1,0,0,-3.2,0,0,GO:0032648,regulation of interferon-beta production,M100,1,0
1,0,0,-3.1,0,0,WP231,TNF alpha signaling pathway,M100,1,0
1,0,0,-2.6,0,0,GO:1901654,response to ketone,M100,1,0
1,0,0,-3.1,0,0,M206,PID PDGFRA PATHWAY,M100,1,0
1,0,0,-4.2,0,0,GO:0030218,erythrocyte differentiation,M100,1,0
1,0,0,-3.8,0,0,R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,M100,1,0
1,0,0,-2.6,0,0,hsa05216,Thyroid cancer,M100,1,0
1,0,0,-2.1,0,0,GO:2000109,regulation of macrophage apoptotic process,M100,1,0
0,1,0,0,-2,0,GO:0042632,cholesterol homeostasis,M010,1,0
1,0,0,-3.4,0,0,hsa05321,Inflammatory bowel disease,M100,1,0
1,0,0,-2.4,0,0,GO:0021766,hippocampus development,M100,1,0
1,0,0,-3.5,0,0,GO:0141091,transforming growth factor beta receptor superfamily signaling pathway,M100,1,0
1,0,0,-3.1,0,0,GO:0001655,urogenital system development,M100,1,0
1,0,0,-2.5,0,0,GO:2000736,regulation of stem cell differentiation,M100,1,0
1,0,0,-2.6,0,0,GO:0030219,megakaryocyte differentiation,M100,1,0
1,0,0,-2.9,0,0,GO:0035270,endocrine system development,M100,1,0
1,0,0,-2,0,0,GO:0021675,nerve development,M100,1,0
1,0,0,-3.6,0,0,GO:0070741,response to interleukin-6,M100,1,0
1,0,0,-2.2,0,0,GO:0060041,retina development in camera-type eye,M100,1,0
1,0,0,-3.6,0,0,hsa04932,Non-alcoholic fatty liver disease,M100,1,0
1,0,0,-3,0,0,M223,PID BETA CATENIN NUC PATHWAY,M100,1,0
1,0,0,-2.1,0,0,GO:0002831,regulation of response to biotic stimulus,M100,1,0
0,1,0,0,-2.2,0,GO:0002763,positive regulation of myeloid leukocyte differentiation,M010,1,0
0,1,0,0,-2.2,0,GO:0031960,response to corticosteroid,M010,1,0
1,0,0,-3.9,0,0,GO:0050728,negative regulation of inflammatory response,M100,1,0
1,0,0,-3.4,0,0,GO:0070102,interleukin-6-mediated signaling pathway,M100,1,0
1,0,0,-2.3,0,0,hsa04934,Cushing syndrome,M100,1,0
1,0,0,-2.6,0,0,WP712,Estrogen signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0038095,Fc-epsilon receptor signaling pathway,M100,1,0
1,0,0,-3.4,0,0,GO:0032944,regulation of mononuclear cell proliferation,M100,1,0
1,0,0,-3,0,0,GO:0043367,"CD4-positive, alpha-beta T cell differentiation",M100,1,0
1,0,0,-3.2,0,0,GO:0051091,positive regulation of DNA-binding transcription factor activity,M100,1,0
1,0,0,-2.5,0,0,CORUM:5228,REL-MAP3K8-RELA-TNIP2-PAPOLA complex,M100,1,0
1,0,0,-2.4,0,0,GO:1900017,positive regulation of cytokine production involved in inflammatory response,M100,1,0
1,0,0,-5.1,0,0,GO:0032868,response to insulin,M100,1,0
0,1,0,0,-2.4,0,GO:0042733,embryonic digit morphogenesis,M010,1,0
1,0,0,-2.8,0,0,WP4396,Nonalcoholic fatty liver disease,M100,1,0
1,0,0,-3.3,0,0,WP3680,Physico chemical features and toxicity associated pathways,M100,1,0
1,0,0,-2.6,0,0,WP3931,Embryonic stem cell pluripotency pathways,M100,1,0
1,0,0,-2.2,0,0,GO:0098609,cell-cell adhesion,M100,1,0
1,0,0,-2.7,0,0,GO:1901861,regulation of muscle tissue development,M100,1,0
1,0,0,-2.5,0,0,WP3407,FTO obesity variant mechanism,M100,1,0
1,0,0,-3,0,0,GO:0043122,regulation of canonical NF-kappaB signal transduction,M100,1,0
1,0,0,-3.3,0,0,R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,M100,1,0
1,0,0,-2.7,0,0,M295,SIG PIP3 SIGNALING IN CARDIAC MYOCTES,M100,1,0
1,0,0,-2.4,0,0,WP5358,JAK STAT signaling in the regulation of Beta cells,M100,1,0
1,0,0,-2.3,0,0,GO:0032735,positive regulation of interleukin-12 production,M100,1,0
1,0,0,-3.1,0,0,GO:0060541,respiratory system development,M100,1,0
1,0,0,-2.9,0,0,GO:0042093,T-helper cell differentiation,M100,1,0
1,0,0,-5.8,0,0,GO:0014013,regulation of gliogenesis,M100,1,0
1,0,0,-4.5,0,0,WP4879,Overlap between signal transduction pathways contributing to LMNA laminopathies,M100,1,0
1,0,0,-2.6,0,0,GO:0021780,glial cell fate specification,M100,1,0
1,0,0,-2.3,0,0,WP4255,Non small cell lung cancer,M100,1,0
0,1,0,0,-2.2,0,GO:0003180,aortic valve morphogenesis,M010,1,0
1,0,0,-3.3,0,0,GO:0009611,response to wounding,M100,1,0
1,0,0,-3.5,0,0,GO:0001709,cell fate determination,M100,1,0
1,0,0,-2.5,0,0,WP2064,Neural crest differentiation,M100,1,0
1,0,0,-3,0,0,GO:0038154,interleukin-11-mediated signaling pathway,M100,1,0
1,0,0,-2.6,0,0,hsa04915,Estrogen signaling pathway,M100,1,0
1,0,0,-3.1,0,0,R-HSA-450282,MAPK targets/ Nuclear events mediated by MAP kinases,M100,1,0
1,0,0,-2.8,0,0,GO:0050851,antigen receptor-mediated signaling pathway,M100,1,0
1,0,0,-2,0,0,GO:0045834,positive regulation of lipid metabolic process,M100,1,0
1,0,0,-2.3,0,0,GO:0042129,regulation of T cell proliferation,M100,1,0
1,0,0,-2.5,0,0,GO:0001704,formation of primary germ layer,M100,1,0
1,0,0,-2.1,0,0,WP384,Apoptosis modulation by HSP70,M100,1,0
1,0,0,-2.9,0,0,GO:0006111,regulation of gluconeogenesis,M100,1,0
1,0,0,-4.3,0,0,WP2034,Leptin signaling pathway,M100,1,0
0,1,0,0,-3,0,GO:0001816,cytokine production,M010,1,0
1,0,0,-5.1,0,0,R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),M100,1,0
1,0,0,-3.1,0,0,GO:0048871,multicellular organismal-level homeostasis,M100,1,0
0,1,0,0,-4.3,0,GO:0003151,outflow tract morphogenesis,M010,1,0
0,1,0,0,-2.2,0,GO:0060537,muscle tissue development,M010,1,0
1,0,0,-4.9,0,0,hsa05160,Hepatitis C,M100,1,0
1,0,0,-4.3,0,0,WP3303,RAC1 PAK1 p38 MMP2 pathway,M100,1,0
0,1,0,0,-2.7,0,GO:0035282,segmentation,M010,1,0
1,0,0,-3.6,0,0,R-HSA-2151201,Transcriptional activation of mitochondrial biogenesis,M100,1,0
1,0,0,-2.7,0,0,R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,M100,1,0
1,0,0,-2.2,0,0,hsa05152,Tuberculosis,M100,1,0
1,0,0,-2.1,0,0,M134,PID TCR RAS PATHWAY,M100,1,0
1,0,0,-2.4,0,0,R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,M100,1,0
1,0,0,-2.8,0,0,GO:0007492,endoderm development,M100,1,0
1,0,0,-3.1,0,0,WP5218,Extrafollicular and follicular B cell activation by SARS CoV 2,M100,1,0
1,0,0,-2.5,0,0,hsa04931,Insulin resistance,M100,1,0
1,0,0,-2.1,0,0,CORUM:2084,NFKB1-NFKB2-REL-RELA-RELB complex,M100,1,0
1,0,0,-7,0,0,WP5381,Smith Magenis and Potocki Lupski syndrome copy number variation,M100,1,0
1,0,0,-2.6,0,0,WP585,Interferon type I signaling pathways,M100,1,0
0,1,0,0,-4.4,0,GO:0048340,paraxial mesoderm morphogenesis,M010,1,0
0,1,0,0,-2.5,0,GO:0071385,cellular response to glucocorticoid stimulus,M010,1,0
1,0,0,-4.7,0,0,WP3646,Hepatitis C and hepatocellular carcinoma,M100,1,0
1,0,0,-2.7,0,0,R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,M100,1,0
1,0,0,-2.9,0,0,CORUM:642,CtBP complex,M100,1,0
1,0,0,-3.2,0,0,GO:0042593,glucose homeostasis,M100,1,0
1,0,0,-5.6,0,0,WP2112,IL 17 signaling pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0010885,regulation of cholesterol storage,M100,1,0
1,0,0,-3.1,0,0,hsa04613,Neutrophil extracellular trap formation,M100,1,0
0,1,0,0,-2.4,0,GO:0044703,multi-organism reproductive process,M010,1,0
1,0,0,-2.9,0,0,WP1528,Physiological and pathological hypertrophy of the heart,M100,1,0
1,0,0,-2.8,0,0,GO:0030162,regulation of proteolysis,M100,1,0
1,0,0,-3.3,0,0,hsa04657,IL-17 signaling pathway,M100,1,0
1,0,0,-2.7,0,0,GO:0002067,glandular epithelial cell differentiation,M100,1,0
1,0,0,-4.1,0,0,M7,PID FCER1 PATHWAY,M100,1,0
1,0,0,-2.7,0,0,R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,M100,1,0
1,0,0,-2.1,0,0,GO:0071774,response to fibroblast growth factor,M100,1,0
1,0,0,-2.8,0,0,R-HSA-8878159,Transcriptional regulation by RUNX3,M100,1,0
1,0,0,-2.1,0,0,WP2815,Mammary gland development pathway Involution Stage 4 of 4,M100,1,0
1,0,0,-2,0,0,GO:1901874,negative regulation of post-translational protein modification,M100,1,0
0,1,0,0,-2.2,0,GO:0046660,female sex differentiation,M010,1,0
1,0,0,-4.3,0,0,R-HSA-9615017,"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",M100,1,0
1,0,0,-2.2,0,0,R-HSA-983231,Factors involved in megakaryocyte development and platelet production,M100,1,0
1,0,0,-3.7,0,0,WP4223,Ras signaling,M100,1,0
1,0,0,-2,0,0,GO:0048872,homeostasis of number of cells,M100,1,0
1,0,0,-3.1,0,0,R-HSA-9614085,FOXO-mediated transcription,M100,1,0
1,0,0,-2.9,0,0,M8626,SIG BCR SIGNALING PATHWAY,M100,1,0
0,1,0,0,-2.1,0,GO:0035051,cardiocyte differentiation,M010,1,0
1,0,0,-2.4,0,0,GO:0030324,lung development,M100,1,0
1,0,0,-2.1,0,0,GO:0071480,cellular response to gamma radiation,M100,1,0
1,0,0,-2.1,0,0,GO:0046716,muscle cell cellular homeostasis,M100,1,0
1,0,0,-7.2,0,0,GO:0030098,lymphocyte differentiation,M100,1,0
1,0,0,-4.4,0,0,GO:0050767,regulation of neurogenesis,M100,1,0
0,1,0,0,-3.8,0,GO:0048514,blood vessel morphogenesis,M010,1,0
1,0,0,-2.9,0,0,M234,PID IL2 STAT5 PATHWAY,M100,1,0
1,0,0,-2.1,0,0,GO:0032736,positive regulation of interleukin-13 production,M100,1,0
1,0,0,-2,0,0,R-HSA-8943724,Regulation of PTEN gene transcription,M100,1,0
1,0,0,-2.1,0,0,R-HSA-3134963,DEx/H-box helicases activate type I IFN and inflammatory cytokines production,M100,1,0
1,0,0,-3.9,0,0,GO:0045666,positive regulation of neuron differentiation,M100,1,0
1,0,0,-3.3,0,0,WP4746,Thyroid hormones production and peripheral downstream signaling effects,M100,1,0
1,0,0,-3.1,0,0,R-HSA-400253,Circadian Clock,M100,1,0
1,0,0,-2.5,0,0,GO:0035710,"CD4-positive, alpha-beta T cell activation",M100,1,0
1,0,0,-3,0,0,GO:1903146,regulation of autophagy of mitochondrion,M100,1,0
1,0,0,-3.6,0,0,WP4961,STING pathway in Kawasaki like disease and COVID 19,M100,1,0
1,0,0,-3.4,0,0,WP2895,Differentiation of white and brown adipocyte,M100,1,0
0,1,0,0,-2.4,0,GO:0051384,response to glucocorticoid,M010,1,0
1,0,0,-3.3,0,0,GO:1902532,negative regulation of intracellular signal transduction,M100,1,0
1,0,0,-2.9,0,0,hsa05131,Shigellosis,M100,1,0
0,1,0,0,-3.7,0,GO:0001944,vasculature development,M010,1,0
1,0,0,-2.3,0,0,GO:0002360,T cell lineage commitment,M100,1,0
1,0,0,-2.3,0,0,GO:0031329,regulation of cellular catabolic process,M100,1,0
1,0,0,-3.4,0,0,R-HSA-9700206,Signaling by ALK in cancer,M100,1,0
1,0,0,-6.4,0,0,GO:0002694,regulation of leukocyte activation,M100,1,0
1,0,0,-2.6,0,0,GO:0001711,endodermal cell fate commitment,M100,1,0
0,1,0,0,-2.9,0,GO:0031668,cellular response to extracellular stimulus,M010,1,0
1,0,0,-5.4,0,0,R-HSA-383280,Nuclear Receptor transcription pathway,M100,1,0
1,0,0,-4.8,0,0,WP4842,Mammalian disorder of sexual development,M100,1,0
1,0,0,-2.1,0,0,GO:0002764,immune response-regulating signaling pathway,M100,1,0
0,1,0,0,-2.3,0,R-HSA-5688426,Deubiquitination,M010,1,0
1,0,0,-4.7,0,0,GO:0071216,cellular response to biotic stimulus,M100,1,0
1,0,0,-2.3,0,0,GO:0051345,positive regulation of hydrolase activity,M100,1,0
1,0,0,-4.1,0,0,R-HSA-400508,"Incretin synthesis, secretion, and inactivation",M100,1,0
1,0,0,-2.9,0,0,CORUM:626,LSD1 complex,M100,1,0
1,0,0,-2.9,0,0,GO:1901863,positive regulation of muscle tissue development,M100,1,0
1,0,0,-2.5,0,0,GO:0033209,tumor necrosis factor-mediated signaling pathway,M100,1,0
1,0,0,-2.6,0,0,GO:0042476,odontogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0044772,mitotic cell cycle phase transition,M100,1,0
1,0,0,-3.6,0,0,GO:0060438,trachea development,M100,1,0
1,0,0,-2.6,0,0,GO:0002366,leukocyte activation involved in immune response,M100,1,0
1,0,0,-2,0,0,R-HSA-877300,Interferon gamma signaling,M100,1,0
0,1,0,0,-2.1,0,GO:0071453,cellular response to oxygen levels,M010,1,0
1,0,0,-2.5,0,0,GO:0031334,positive regulation of protein-containing complex assembly,M100,1,0
1,0,0,-2.3,0,0,R-HSA-3214841,PKMTs methylate histone lysines,M100,1,0
1,0,0,-3.1,0,0,WP4336,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,M100,1,0
1,0,0,-2.8,0,0,GO:0007178,transmembrane receptor protein serine/threonine kinase signaling pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0007179,transforming growth factor beta receptor signaling pathway,M100,1,0
1,0,0,-2.6,0,0,GO:0043467,regulation of generation of precursor metabolites and energy,M100,1,0
1,0,0,-2,0,0,GO:0014033,neural crest cell differentiation,M100,1,0
0,1,0,0,-2.7,0,GO:0014855,striated muscle cell proliferation,M010,1,0
1,0,0,-2.3,0,0,WP722,Serotonin HTR1 group and FOS pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0043031,negative regulation of macrophage activation,M100,1,0
1,0,0,-4.1,0,0,WP4211,Transcriptional cascade regulating adipogenesis,M100,1,0
1,0,0,-3,0,0,WP2817,Mammary gland development pathway Pregnancy and lactation Stage 3 of 4,M100,1,0
1,0,0,-2.1,0,0,GO:0050900,leukocyte migration,M100,1,0
1,0,0,-3,0,0,GO:0050867,positive regulation of cell activation,M100,1,0
1,0,0,-2.3,0,0,WP4585,Cancer immunotherapy by PD 1 blockade,M100,1,0
1,0,0,-2.4,0,0,R-HSA-9634638,Estrogen-dependent nuclear events downstream of ESR-membrane signaling,M100,1,0
1,0,0,-2.9,0,0,GO:0071425,hematopoietic stem cell proliferation,M100,1,0
1,0,0,-2.2,0,0,GO:0010660,regulation of muscle cell apoptotic process,M100,1,0
1,0,0,-4.1,0,0,GO:0048715,negative regulation of oligodendrocyte differentiation,M100,1,0
1,0,0,-2.5,0,0,CORUM:2536,PLC-gamma-2-SLP-76-Lyn-Grb2 complex,M100,1,0
0,1,0,0,-4.7,0,GO:0048762,mesenchymal cell differentiation,M010,1,0
1,0,0,-3,0,0,GO:0060397,growth hormone receptor signaling pathway via JAK-STAT,M100,1,0
1,0,0,-5.6,0,0,hsa05213,Endometrial cancer,M100,1,0
1,0,0,-2.9,0,0,GO:0032922,circadian regulation of gene expression,M100,1,0
1,0,0,-3.8,0,0,GO:0034101,erythrocyte homeostasis,M100,1,0
1,0,0,-2.9,0,0,WP363,Wnt signaling pathway,M100,1,0
1,0,0,-2.4,0,0,WP313,Hepatocyte growth factor receptor signaling,M100,1,0
1,0,0,-4.1,0,0,WP4816,TGF beta receptor signaling in skeletal dysplasias,M100,1,0
1,0,0,-2.3,0,0,GO:0002053,positive regulation of mesenchymal cell proliferation,M100,1,0
1,0,0,-6.9,0,0,R-HSA-2559583,Cellular Senescence,M100,1,0
1,0,0,-2.1,0,0,GO:0006930,"substrate-dependent cell migration, cell extension",M100,1,0
1,0,0,-3.3,0,0,GO:0050864,regulation of B cell activation,M100,1,0
1,0,0,-2.7,0,0,GO:2000177,regulation of neural precursor cell proliferation,M100,1,0
1,0,0,-2.3,0,0,WP400,p38 MAPK signaling pathway,M100,1,0
1,0,0,-5.1,0,0,CORUM:3045,hs4 enhancer complex (faster migrating complex),M100,1,0
1,0,0,-3,0,0,WP289,Myometrial relaxation and contraction pathways,M100,1,0
1,0,0,-2.8,0,0,hsa05140,Leishmaniasis,M100,1,0
1,0,0,-2.4,0,0,GO:0000278,mitotic cell cycle,M100,1,0
1,0,0,-3.7,0,0,GO:0014015,positive regulation of gliogenesis,M100,1,0
1,0,0,-3.4,0,0,GO:0021953,central nervous system neuron differentiation,M100,1,0
1,0,0,-3.1,0,0,R-HSA-400206,Regulation of lipid metabolism by PPARalpha,M100,1,0
1,0,0,-2.6,0,0,GO:0035024,negative regulation of Rho protein signal transduction,M100,1,0
1,0,0,-2.1,0,0,GO:0046533,negative regulation of photoreceptor cell differentiation,M100,1,0
1,0,0,-2.2,0,0,R-HSA-9679506,SARS-CoV Infections,M100,1,0
1,0,0,-3.2,0,0,hsa04211,Longevity regulating pathway,M100,1,0
0,1,0,0,-2.2,0,GO:0001823,mesonephros development,M010,1,0
1,0,0,-5.5,0,0,GO:0030855,epithelial cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0046532,regulation of photoreceptor cell differentiation,M100,1,0
1,0,0,-6,0,0,R-HSA-8853884,Transcriptional Regulation by VENTX,M100,1,0
0,1,0,0,-3.8,0,GO:0001569,branching involved in blood vessel morphogenesis,M010,1,0
1,0,0,-2.2,0,0,GO:2001233,regulation of apoptotic signaling pathway,M100,1,0
0,1,0,0,-3.3,0,GO:0010717,regulation of epithelial to mesenchymal transition,M010,1,0
1,0,0,-2.3,0,0,GO:1903047,mitotic cell cycle process,M100,1,0
1,0,0,-4.4,0,0,GO:0048534,hematopoietic or lymphoid organ development,M100,1,0
0,1,0,0,-3.5,0,GO:0046879,hormone secretion,M010,1,0
1,0,0,-3.1,0,0,GO:0003310,pancreatic A cell differentiation,M100,1,0
1,0,0,-2.1,0,0,WP3995,Prion disease pathway,M100,1,0
1,0,0,-4.5,0,0,GO:0045665,negative regulation of neuron differentiation,M100,1,0
1,0,0,-3,0,0,GO:0032667,regulation of interleukin-23 production,M100,1,0
1,0,0,-2.4,0,0,WP2881,Estrogen receptor pathway,M100,1,0
1,0,0,-2.9,0,0,GO:0048384,retinoic acid receptor signaling pathway,M100,1,0
0,1,0,0,-2.3,0,GO:0001657,ureteric bud development,M010,1,0
1,0,0,-2.9,0,0,GO:0048588,developmental cell growth,M100,1,0
1,0,0,-2.1,0,0,GO:0045667,regulation of osteoblast differentiation,M100,1,0
1,0,0,-5.1,0,0,GO:0031641,regulation of myelination,M100,1,0
1,0,0,-2.1,0,0,GO:0042552,myelination,M100,1,0
1,0,0,-4.7,0,0,WP4337,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,M100,1,0
1,0,0,-3.4,0,0,GO:1904888,cranial skeletal system development,M100,1,0
0,1,0,0,-2.1,0,GO:0043525,positive regulation of neuron apoptotic process,M010,1,0
0,1,0,0,-2.4,0,WP1982,Sterol regulatory element binding proteins SREBP signaling,M010,1,0
1,0,0,-4.8,0,0,GO:0050865,regulation of cell activation,M100,1,0
0,1,0,0,-2.2,0,GO:0036294,cellular response to decreased oxygen levels,M010,1,0
1,0,0,-3.7,0,0,WP2637,Interleukin 1 IL 1 structural pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0050832,defense response to fungus,M100,1,0
1,0,0,-2.4,0,0,R-HSA-9669938,Signaling by KIT in disease,M100,1,0
1,0,0,-4.7,0,0,GO:0032479,regulation of type I interferon production,M100,1,0
1,0,0,-2.9,0,0,GO:0045471,response to ethanol,M100,1,0
1,0,0,-2.1,0,0,GO:0045765,regulation of angiogenesis,M100,1,0
1,0,0,-2,0,0,GO:1901342,regulation of vasculature development,M100,1,0
0,1,0,0,-2.1,0,GO:0010595,positive regulation of endothelial cell migration,M010,1,0
1,0,0,-5.4,0,0,GO:0021895,cerebral cortex neuron differentiation,M100,1,0
1,0,0,-2.9,0,0,hsa04664,Fc epsilon RI signaling pathway,M100,1,0
1,0,0,-6.7,0,0,GO:0045321,leukocyte activation,M100,1,0
1,0,0,-2.1,0,0,GO:0062208,positive regulation of pattern recognition receptor signaling pathway,M100,1,0
0,1,0,0,-3.3,0,GO:0048339,paraxial mesoderm development,M010,1,0
1,0,0,-2.1,0,0,GO:0001889,liver development,M100,1,0
0,1,0,0,-2.2,0,GO:0001756,somitogenesis,M010,1,0
1,0,0,-2.4,0,0,hsa04014,Ras signaling pathway,M100,1,0
1,0,0,-3.2,0,0,GO:1900015,regulation of cytokine production involved in inflammatory response,M100,1,0
1,0,0,-2,0,0,GO:0014003,oligodendrocyte development,M100,1,0
1,0,0,-3.4,0,0,GO:0071378,cellular response to growth hormone stimulus,M100,1,0
1,0,0,-3.3,0,0,WP4754,IL 18 signaling pathway,M100,1,0
1,0,0,-4.1,0,0,M22,PID GMCSF PATHWAY,M100,1,0
1,0,0,-3.4,0,0,GO:0002223,stimulatory C-type lectin receptor signaling pathway,M100,1,0
1,0,0,-2.5,0,0,GO:0071394,cellular response to testosterone stimulus,M100,1,0
1,0,0,-2.9,0,0,M143,PID IL2 PI3K PATHWAY,M100,1,0
1,0,0,-2.7,0,0,WP2261,Glioblastoma signaling pathways,M100,1,0
1,0,0,-2.8,0,0,hsa05206,MicroRNAs in cancer,M100,1,0
1,0,0,-7.1,0,0,GO:0046649,lymphocyte activation,M100,1,0
0,1,0,0,-2.6,0,GO:0023061,signal release,M010,1,0
1,0,0,-2.1,0,0,GO:0046637,regulation of alpha-beta T cell differentiation,M100,1,0
0,1,0,0,-2.1,0,GO:0003279,cardiac septum development,M010,1,0
1,0,0,-2.2,0,0,GO:0062013,positive regulation of small molecule metabolic process,M100,1,0
1,0,0,-2.5,0,0,WP4562,Canonical NF kB pathway,M100,1,0
0,1,0,0,-3.3,0,GO:0061180,mammary gland epithelium development,M010,1,0
1,0,0,-2.4,0,0,GO:2000191,regulation of fatty acid transport,M100,1,0
1,0,0,-2.5,0,0,GO:0048708,astrocyte differentiation,M100,1,0
1,0,0,-2.8,0,0,GO:0048713,regulation of oligodendrocyte differentiation,M100,1,0
1,0,0,-4.3,0,0,WP710,DNA damage response only ATM dependent,M100,1,0
1,0,0,-2.7,0,0,M279,PID RB 1PATHWAY,M100,1,0
1,0,0,-2.9,0,0,WP299,Nuclear receptors in lipid metabolism and toxicity,M100,1,0
1,0,0,-2.9,0,0,hsa05208,Chemical carcinogenesis - reactive oxygen species,M100,1,0
1,0,0,-2.3,0,0,M70,PID PS1 PATHWAY,M100,1,0
1,0,0,-2,0,0,GO:0001961,positive regulation of cytokine-mediated signaling pathway,M100,1,0
1,0,0,-4.1,0,0,WP254,Apoptosis,M100,1,0
0,1,0,0,-3.5,0,GO:0003208,cardiac ventricle morphogenesis,M010,1,0
1,0,0,-3.7,0,0,hsa04668,TNF signaling pathway,M100,1,0
1,0,0,-2.1,0,0,WP4919,Neuroinflammation,M100,1,0
1,0,0,-4.2,0,0,R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,M100,1,0
1,0,0,-4.6,0,0,M92,PID ANGIOPOIETIN RECEPTOR PATHWAY,M100,1,0
1,0,0,-4.1,0,0,M278,PID RAC1 PATHWAY,M100,1,0
1,0,0,-2.5,0,0,WP3672,lncRNA mediated mechanisms of therapeutic resistance,M100,1,0
1,0,0,-2.1,0,0,GO:0021529,spinal cord oligodendrocyte cell differentiation,M100,1,0
1,0,0,-3,0,0,GO:0043587,tongue morphogenesis,M100,1,0
1,0,0,-2.1,0,0,CORUM:643,CtBP core complex,M100,1,0
1,0,0,-3.1,0,0,hsa04933,AGE-RAGE signaling pathway in diabetic complications,M100,1,0
1,0,0,-4.8,0,0,WP5322,CKAP4 signaling pathway map,M100,1,0
1,0,0,-2.9,0,0,WP3658,Wnt beta catenin signaling pathway in leukemia,M100,1,0
1,0,0,-2.5,0,0,GO:0071773,cellular response to BMP stimulus,M100,1,0
1,0,0,-2.6,0,0,GO:0009620,response to fungus,M100,1,0
1,0,0,-3.4,0,0,GO:0042475,odontogenesis of dentin-containing tooth,M100,1,0
1,0,0,-2.5,0,0,R-HSA-9707616,Heme signaling,M100,1,0
1,0,0,-3.7,0,0,hsa04066,HIF-1 signaling pathway,M100,1,0
0,1,0,0,-2.2,0,GO:0051145,smooth muscle cell differentiation,M010,1,0
1,0,0,-2.4,0,0,R-HSA-4641265,Repression of WNT target genes,M100,1,0
1,0,0,-2,0,0,GO:0070828,heterochromatin organization,M100,1,0
1,0,0,-3,0,0,hsa04926,Relaxin signaling pathway,M100,1,0
1,0,0,-3,0,0,GO:0002634,regulation of germinal center formation,M100,1,0
1,0,0,-2.1,0,0,GO:0016444,somatic cell DNA recombination,M100,1,0
0,1,0,0,-2.5,0,GO:0010634,positive regulation of epithelial cell migration,M010,1,0
1,0,0,-3,0,0,hsa04137,Mitophagy - animal,M100,1,0
0,1,0,0,-4.4,0,GO:0060986,endocrine hormone secretion,M010,1,0
1,0,0,-2.6,0,0,WP5063,FOXP3 in COVID 19,M100,1,0
0,1,0,0,-3.3,0,GO:0031669,cellular response to nutrient levels,M010,1,0
0,1,0,0,-2.3,0,GO:0072164,mesonephric tubule development,M010,1,0
1,0,0,-2.2,0,0,R-HSA-2173796,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,M100,1,0
1,0,0,-3.4,0,0,R-HSA-9725370,Signaling by ALK fusions and activated point mutants,M100,1,0
1,0,0,-3.4,0,0,GO:0002695,negative regulation of leukocyte activation,M100,1,0
1,0,0,-2.4,0,0,GO:0050853,B cell receptor signaling pathway,M100,1,0
1,0,0,-5.3,0,0,GO:0032675,regulation of interleukin-6 production,M100,1,0
1,0,0,-5.8,0,0,WP23,B cell receptor signaling pathway,M100,1,0
1,0,0,-2.3,0,0,hsa05142,Chagas disease,M100,1,0
1,0,0,-2.3,0,0,R-HSA-3560801,Defective B3GAT3 causes JDSSDHD,M100,1,0
1,0,0,-2.1,0,0,WP2036,TNF related weak inducer of apoptosis TWEAK signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0002286,T cell activation involved in immune response,M100,1,0
1,0,0,-2.3,0,0,GO:0060612,adipose tissue development,M100,1,0
1,0,0,-2.1,0,0,R-HSA-8939245,RUNX1 regulates transcription of genes involved in BCR signaling,M100,1,0
1,0,0,-3.3,0,0,R-HSA-1592230,Mitochondrial biogenesis,M100,1,0
1,0,0,-3.9,0,0,GO:0071354,cellular response to interleukin-6,M100,1,0
1,0,0,-3.5,0,0,R-HSA-983705,Signaling by the B Cell Receptor (BCR),M100,1,0
1,0,0,-2.5,0,0,GO:0034224,cellular response to zinc ion starvation,M100,1,0
0,1,0,0,-2.4,0,GO:0033002,muscle cell proliferation,M010,1,0
1,0,0,-2.1,0,0,GO:0002562,somatic diversification of immune receptors via germline recombination within a single locus,M100,1,0
1,0,0,-3.4,0,0,GO:1903555,regulation of tumor necrosis factor superfamily cytokine production,M100,1,0
1,0,0,-2.5,0,0,GO:0032655,regulation of interleukin-12 production,M100,1,0
1,0,0,-3.5,0,0,GO:0071322,cellular response to carbohydrate stimulus,M100,1,0
1,0,0,-3.3,0,0,GO:0007623,circadian rhythm,M100,1,0
1,0,0,-4,0,0,R-HSA-975871,MyD88 cascade initiated on plasma membrane,M100,1,0
1,0,0,-3.5,0,0,GO:0032755,positive regulation of interleukin-6 production,M100,1,0
1,0,0,-4.2,0,0,GO:0031349,positive regulation of defense response,M100,1,0
1,0,0,-3.3,0,0,GO:0002237,response to molecule of bacterial origin,M100,1,0
1,0,0,-3.2,0,0,R-HSA-1834949,Cytosolic sensors of pathogen-associated DNA,M100,1,0
1,0,0,-2.4,0,0,R-HSA-9607240,FLT3 Signaling,M100,1,0
1,0,0,-2.6,0,0,GO:0045088,regulation of innate immune response,M100,1,0
1,0,0,-3.5,0,0,GO:0032680,regulation of tumor necrosis factor production,M100,1,0
1,0,0,-3.6,0,0,WP3599,Transcription factor regulation in adipogenesis,M100,1,0
1,0,0,-3.8,0,0,WP3584,MECP2 and associated Rett syndrome,M100,1,0
1,0,0,-5.3,0,0,GO:0001775,cell activation,M100,1,0
1,0,0,-3.4,0,0,GO:0001779,natural killer cell differentiation,M100,1,0
0,1,0,0,-2.9,0,GO:0001707,mesoderm formation,M010,1,0
0,1,0,0,-3,0,WP4329,miRNA role in immune response in sepsis,M010,1,0
0,1,0,0,-2.2,0,GO:0003203,endocardial cushion morphogenesis,M010,1,0
1,0,0,-2.1,0,0,GO:0043491,phosphatidylinositol 3-kinase/protein kinase B signal transduction,M100,1,0
1,0,0,-5,0,0,hsa04935,"Growth hormone synthesis, secretion and action",M100,1,0
1,0,0,-2.6,0,0,GO:0007405,neuroblast proliferation,M100,1,0
1,0,0,-2.6,0,0,GO:0032656,regulation of interleukin-13 production,M100,1,0
1,0,0,-2.1,0,0,GO:0061196,fungiform papilla development,M100,1,0
1,0,0,-3.2,0,0,GO:0010721,negative regulation of cell development,M100,1,0
1,0,0,-3.1,0,0,GO:0090336,positive regulation of brown fat cell differentiation,M100,1,0
1,0,0,-3.5,0,0,GO:0009896,positive regulation of catabolic process,M100,1,0
1,0,0,-5.2,0,0,GO:0051090,regulation of DNA-binding transcription factor activity,M100,1,0
